

BIBLIOGRAPHY
Connecticut Tumor Registry
State of Connecticut Department of Public Health

1. Griswold MH. The cancer program in Connecticut. *JAMA* 1938; 110:221-4.
2. Macdonald EJ. The cancer situation in Connecticut. *Conn Health Bull* 1942; 56.
3. Griswold MH. A cancer program in action. *Conn Health Bull* 1943; 57:131-3.
4. Macdonald E. Facts about cancer. *Conn Health Bull* 1943; 57.
5. Macdonald EJ. Eight years' experience in cancer in twenty-one Conn. hospitals. *Conn State Med J* 1943; 7:536.
6. Macdonald EJ. Improvements in services rendered in Conn. hospitals to individuals with cancer. *Conn Health Bull* 1943; 57.
7. Griswold MH. Research is key to Connecticut system of cancer control. *Hospitals: the journal of the American Hospital Association* 1944; 18.
8. Macdonald E. Connecticut as a cooperative entity for the control of cancer. *Conn Health Bull* 1944; 58:191-2.
9. Macdonald E. A report of living individuals who had proved cancer. *Conn Health Bull* 1944; 58:82-4.
10. Macdonald E. Survival rates of individuals who have had proved cancer in Connecticut 1935-1942. *Conn Health Bull* 1944; 58:256-60.
11. Macdonald EJ. The state-wide cancer record registry in Connecticut. *Med Wom J* 1944; 51.
12. Griswold MH. Cancer of the prostate in Connecticut. *Conn State Med J* 1946; 10:106-109.
13. Griswold MH. Cancer recorded from each town in state. *Conn Health Bull* 1946; 60:90-2.
14. Griswold MH. The expansion of the Connecticut cancer program. *Conn State Med J* 1946; 10:18-20.
15. Martin H. Mouth cancer and the dentist. *J Am Dent Assoc* 1946; 33:845-61.
16. Macdonald E. Meaning of adjusted rates for cancer. *Conn Health Bull* 1946; 60:279-82.
17. Griswold MH. A mutual educational program. *Conn Health Bull* 1947; 61.
18. Griswold MH, Macdonald EJ. The Conn. Cancer Record Registry - How it functions. *Conn State Med J* 1947; 11:344-7.
19. Macdonald E. The incidence of cancer of the breast among women. *Conn Health Bull* 1947; 66:174-6.
20. Macdonald EJ. Changing reasons for cancer patient delay. *Conn Health Bull* 1947; 61:99-101.
21. Connecticut State Dental Society Tumor Committee. *Cancer, A Handbook for Dentists*. 1948; 1-52.
22. Griswold MH. Evaluation of cancer control methods in Conn. *JAMA* 1948; 138:881-4.

23. Macdonald E. The estimated number of individuals treated for cancer needing nursing service. *Conn. Health Bulletin* 1948; 62:63-7.
24. Macdonald E. The present incidence and survival picture in cancer and the promise of improved prognosis. *Bull Am Coll Surg* 1948; 33:75-93.
25. Macdonald EJ. Malignant melanoma in Connecticut *Ann NY Acad Sci* 1948; 4:71-81.
26. Ottenheimer EJ. Cancer of the colon and rectum. *Conn State Med J* 1948; 12:1086-90.
27. Haenszel WM. Trends in Connecticut vital statistics - XVII. Mortality from cancer. *Conn Health Bull* 1950; 64:96-104.
28. Pollack ES. Cancer case reporting in relation to deaths from cancer. *Conn Health Bull* 1950; 64:91-5.
29. Staff of Division of Cancer and Other Diseases. *Cancer in Connecticut-1949*. 1950; 1-30.
30. Wilder CC. Male and female cancer mortality trends in Connecticut, 1937-1948. *Conn Health Bull* 1950; 64:157-62.
31. Griswold MH. Fifteen years' experience with the Conn. Cancer Registry. *Conn Health Bull* 1951; 65.
32. Wilder CS. Incidence and the Connecticut Control Program. *Conn Health Bull* 1951; 65.
33. Griswold MH. Cancer of the prostate in infants and children. *JAMA* 1952; 150:791.
34. Pollack ES. Lymphomas: Fifteen years' experience in Connecticut. *Conn Health Bull* 1952; 66.
35. Griswold MH. Cancer morbidity records. *J Mich State Med Soc* 1953; 52:274-5.
36. Pollack ES. Cancer survival picture brightens. *Conn Health Bull* 1953; 67.
37. Staff of the Division of Cancer and Other Chronic Diseases. *Cancer in Connecticut-1950*. 1953; 1-32.
38. Wilder CS. Cancer in Connecticut towns: I. Cases reported by hospitals. *Conn Health Bull* 1953; 67.
39. Wilder CS. Cancer in Connecticut Towns: II. Mortality from cancer. *Conn Health Bull* 1953; 67.
40. Pollack ES. The effect of age and site on life expectancy of cancer patients. *Conn Health Bull* 1954; 68:193-200.
41. Curran TL. Laryngeal carcinoma in Connecticut; observations with particular reference to its surgical treatment. *AMA Arch Otolaryngol* 1955; 62:145-53.
42. Griswold MH. Hospitalization of cancer patients. *Conn Health Bull* 1955; 69:291-319.
43. Griswold MH. Lung cancer in Connecticut on increase. *Conn Health Bull* 1955; 69:65-9.
44. Griswold MH, Wilder CS, Cutler SJ, Pollack ES. *Cancer in Connecticut. 1935-1951*. 1955; 1-141.
45. Ottenheimer EJ, Oughterson A W. Observations on cancer of the colon and rectum in Connecticut - An analysis based on 5572 proved cases. *N Engl J Med* 1955; 252:561-7.
46. Cutler SJ, Griswold MH, Shimkin MD. Survival in untreated and treated cancer. *Ann Intern Med* 1956; 45:255-67.

47. Eisenberg H. Cancer diagnosis in relation to hospital. *Conn Health Bull* 1956; 70:305-10.
48. Greenberg RA. Mass survey detected lung cancer in Connecticut, 1949-1953. *Conn State Med J* 1956; 20:857-863.
49. Griswold MH. Environmental cancer in Connecticut: I. The survey project plan. *Conn Health Bull* 1956; 70:91-100.
50. Griswold MH, Cutler SJ. The Connecticut cancer register - Seventeen years of experience. *Conn State Med J* 1956; 20:366-72.
51. Griswold MH, Cutler SJ, Eisenberg H. Improvements in cancer survival rates. *N Engl J Med* 1956; 254:1062-8.
52. Keogh JR. Cancer mortality trends by sex, Connecticut 1937-1954. *Conn Health Bull* 1956; 70.
53. Wilder CS. Environmental cancer in Connecticut: II. Differences in incidence of cancer among areas. *Conn Health Bull* 1956; 70:143-50.
54. Wilder CS. Estimated cancer survival rates confirmed. *Conn Health Bull* 1956; 70.
55. Cutler SJ, Griswold MH, Eisenberg H. An interpretation of survival rates: Cancer of the breast. *J Natl Cancer Inst* 1957; 19:1107-17.
56. Greenberg R. Trend in cancer incidence by sex and site, Connecticut, 1935-1954. *Conn Health Bull* 1958; 72:79-86.
57. Keogh JR. Progress in cancer control evident from increased hospital study and care of cases. *Conn Health Bull* 1957; 71:267-70.
58. Eisenberg H, Currie JB. Cancer mortality in later life. *Conn Health Bull* 1958; 72:315-326.
59. Eisenberg H, Greenberg RA, Yesner R. ABO blood groups and gastric cancer. *J Chronic Dis* 1958; 8:342-8.
60. Ryan AJ, Griswold MH, Allen EP, Katzenstein R, Greenberg R, Keogh J, Wilder C. Breast cancer in Connecticut 1935-1953 - Study of 8,396 proved cases. *JAMA* 1958; 167:298-307.
61. Cutler SJ, Ederer F, Griswold MH, Greenberg RA. Survival of breast cancer patients in Connecticut, 1935-1954. *J Natl Cancer Inst* 1959; 23:1137-56.
62. Greenberg RA. The Connecticut Tumor Registry. *Conn Health Bull* 1959; 73.
63. Greenberg RA, Honeyman M. Lung cancer a growing problem. *Conn Health Bull* 1959; 73.
64. White C, Eisenberg H. ABO blood groups and cancer of the stomach. *Yale J Biol Med* 1959; 32:58-61.
65. Cutler SJ, Ederer F, Griswold MH, Greenberg RA. Survival of patients with ovarian cancer, 1935-1954. *J Natl Cancer Inst* 1960; 24:541-9.
66. Cutler SJ, Ederer F, Griswold MH, Greenberg RA. Survival of patients with uterine cancer, 1935-1954. *J Natl Cancer Inst* 1960; 24:519-39.
67. Ederer F, Cutler SJ, Eisenberg H, Keogh J. Survival of patients with cancer of the stomach. Connecticut 1935-1954. *J Natl Cancer Inst* 1960; 25:1005-21.

68. Keogh J. The systematic follow-up of cancer. *Conn Health Bull* 1960; 74.
69. Mustacchi P, Cutler SJ. Survival of patients with cancer of the thyroid gland. *JAMA* 1960; 173:1795-8.
70. Axtell LM, Breslow L, Eisenberg H. Trends in survival rates of cancer patients: Connecticut and California. *Natl Cancer Inst Monogr* 1961; 6:49-67.
71. Bailar JC 3rd. Uterine cancer in Connecticut: Late deaths among five-year survivors. *J Natl Cancer Inst* 1961; 27:239-57.
72. Bailar JC 3rd, Rice SL. Survival of uterine cancer patients in different-sized hospitals. *Public Health Rep* 1961; 76:987-94.
73. Ederer F, Cutler SJ, Eisenberg H, Keogh JR. Survival of patients with cancer of the large intestine and rectum, Connecticut. 1935-1954. *J Natl Cancer Inst* 1961; 26:489-510.
74. Bailar JC, Honeyman MS, Eisenberg H. Incidence and mortality rates for leukemia and lymphoma. *Public Health Rep* 1962; 77:281-6.
75. Bailar JC 3rd, Rice SL. Geographic variation in uterine cancer incidence in Connecticut. *Public Health Rep* 1962; 77:157-63.
76. Eisenberg H. Connecticut participates in international cancer studies. *Conn Health Bull* 1962; 76.
77. Honeyman MS. The familial implications of breast cancer in man. *Conn Health Bull* 1962; 76.
78. Odoardo DF. Lung cancer mortality, 1949-1961. *Conn Health Bull* 1962; 76:111-8.
79. Ryan AJ, Curry J, Eisenberg H. Castration following radical mastectomy for breast cancer - Preliminary study. *Conn Med* 1962; 16:71-8.
80. Bailar JC 3rd. The incidence of independent tumors among uterine cancer patients. *Cancer* 1963; 16:842-53.
81. Bailar JC 3rd, Loury R, Goldenberg IS. A note on follow-ups of lost patients. *Natl Cancer Inst Monogr* 1963; 6:123-8.
82. Campbell PC. The Connecticut Tumor Registry today - The growth of the registry. *Conn Health Bull* 1963; 77.
83. Ederer F, Cutler SJ, Goldenberg IS, Eisenberg H. Causes of death among long-term survivors from breast cancer in Connecticut. *J Natl Cancer Inst* 1963; 30:933-47.
84. Eisenberg H. Cancer control: Some opportunities for continued progress. *Conn Health Bull* 1963; 77:179-186.
85. Eisenberg H. Connecticut's contribution to the eighth international cancer congress. *Conn Health Bulletin*, 1963; 77.
86. Eisenberg H, Mork T, Connelly PR. Cancer of the large intestine and rectum: Comparative data from Connecticut and Norway, 1953-1958. *Natl Cancer Inst Monogr* 1963; 15:301-19.
87. Kralits LA. Cancer statistics by the IBM data processing method. *Conn Health Bull* 1963; 77.
88. Eisenberg H, Cutler SJ, Axtell L. Survival patterns for some forms of cancer. *Trans Assoc Life Insur Med Dir Am* 1964; 126-146.

89. Greenberg RA. The occurrence of multiple primary cancers in Connecticut, 1935-1954. *Conn Health Bull* 1963; 77.
90. Eisenberg H, Keogh JR, Foote FM. Secular trends in survival: Five years and later: Cancer patients drawn from a defined population, Connecticut, U.S.A. *Acta Unio Int Contra Cancrum* 1963; 19:1467-78.
91. Barnett RN, Eisenberg H. Breast carcinoma: histologic grading and survival in a large series of cases. *Conn Med* 1964; 28:123-5.
92. Cutler SJ, Eisenberg H. Cancer in the ages. *Annals of the N.Y. Academy of Science* 1964; 114:771-781.
93. Eisenberg H. The Connecticut Registry - Its importance and contributions to oncology. *Conn Med* 1964; 28:119-22.
94. Eisenberg H, Cutler SJ, Axtell L. Differential survival of cancer for selected sites. *Proc Int Cong Life Assur Med* 1964; 121-34.
95. Eisenberg H, Heise H. End results in cancer of the prostate and the urinary bladder, 1940 to 1959. *Proc Natl Cancer Conf* 1964; 5:331-40.
96. Eisenberg H, Odorado DF, Campbell PC. *Cancer in Connecticut - mortality data, 1949-1961*. 1964; 1-104.
97. Eisenberg H, Shames JM, Holloway WL, Barrett HS. Cancer of the bronchus and lung: Connecticut 1935-1959. *J Chronic Dis* 1964; 17:1033-54.
98. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut-1960*. 1964; 1-93.
99. Kuehn PG, Beckett R, Eisenberg H, Reed JF. Epidermoid carcinoma of the perianal skin and anal canal - A review of 157 cases. *N Engl J Med* 1964; 270:614-7.
100. Mason MJ, Bailar JC 3rd, Eisenberg H. Geographic variation in the incidence of esophageal cancer. *J Chronic Dis* 1964; 17:667-76.
101. Mersheimer WL, Ringel A, Eisenberg H. Some characteristics of multiple primary cancers. *Ann NY Acad Sci* 1964; 114:896-921.
102. Bailar JC 3rd, Eisenberg H. Uterine tumors of unspecified origin. *Cancer* 1965; 18:589-91.
103. Ederer F, Myers MH, Eisenberg H, Campbell PC. Temporal spatial distributions of leukemia and lymphoma in Conn. *J Natl Cancer Inst* 1965; 35: 625-9.
104. Eisenberg H. Trends in mortality by age for selected cancer sites, 1949-1961. *Conn Health Bull* 1965; 79.
105. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut-1961*, 1965; 1-91.
106. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut – Supplementary Mortality Data 1949-1962*. 1965; 1-83.
107. Kuehn PG, Beckett R, Eisenberg H, Reed JF. Hematogenous metastases from epidermoid carcinoma of the anal canal. *Am J Surg* 1965; 109:445-9.

108. Bailar JC 3rd, Thomas LB, Thomson AD, Eisenberg H, Vick RM. Morphology and survival rates of cervical cancer in Connecticut and Southwest England. *Natl Cancer Inst Monogr* 1966; 19:385-403.
109. Campbell P. Suicides among cancer patients. *Conn Health Bull* 1966; 80:207-12.
110. Eisenberg H. The usefulness of the Connecticut Central Tumor Registry. *Conn Med* 1966; 30:412-7.
111. Eisenberg H. The value of a central tumor registry. *Ind J Cancer* 1966; 3:75-93.
112. Eisenberg H, Goldenberg I. A measurement of the quality of survival of breast cancer patients. In: *Clinical Evaluation in Breast Cancer* (Eds. Hayward JL, Bulbrook RD) 1966; 93-108.
113. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut, Incidence and Rates, 1935-1962*. 1966; 1-69.
114. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut, 1963*. 1966; 1-129.
115. Foote FM, Eisenberg H, Honeyman MS. Trends in cancer incidence and survival in Connecticut. *Cancer* 1966; 19:1573-7.
116. Janus ZL, Bailar JC 3rd, Eisenberg H. ABO blood groups and multiple cancers. *Conn Med* 1966; 30:475-6.
117. Truax H, Barnett RN, Hukill PB, Campbell PC, Eisenberg H. The effect of inaccurate pathological diagnosis on survival statistics for melanoma - survey of cases in the Connecticut Tumor Registry. *Cancer* 1966; 19:1543-7.
118. Wynder EL, Graham S, Eisenberg H. Conference on the etiology of gastrointestinal tract cancer. *Cancer* 1966; 19:1561-6.
119. Connelly RR. Cancer mortality among the foreign-born in Connecticut. *Conn Health Bull* 1967; 81:315-22.
120. Cutler SJ, Heise H, Eisenberg H. Childhood leukemia in Connecticut, 1940-1962. *Blood* 1967; 30:1-25.
121. Eisenberg H. Thoughts about "Cancer facts by experts." *Conn Health Bull* 1967; 81:373-80.
122. Eisenberg H, Campbell P, Flannery J. *Cancer in Connecticut, incidence characteristics 1935-1962*. 1967; 1-97.
123. Eisenberg H, Connelly R. Some preliminary data on the postmastectomy treatment of female breast cancer in Connecticut. *Conn Med* 1967; 31:193-5.
124. Eisenberg H, Foote FM. Cancer trends as determined by the Connecticut State Tumor Registry. *Prog Clin Cancer* 1967; 3:51-78.
125. Eisenberg H, Staff of Chronic Disease Control Section. *Cancer in Connecticut, 1964*. 1967; 1-136.
126. Eisenberg H, Sullivan P, Foote FM. Trends in survival of digestive system cancer patients in Connecticut 1935 to 1962. *Gastroenterol* 1967; 53:528-46.
127. Janus ZL, Bailar JC 3rd, Eisenberg H. Blood groups and uterine cancer. *Am J Epidemiol* 1967; 86:569-78.
128. Moldow RE. A preliminary report - Leukemia case surveillance in Connecticut, July 1, 1966 - June 30, 1967. *Conn Health Bull* 1967; 81.

129. Shedd DP, von Essen CF, Eisenberg H. Cancer of the nasopharynx in Connecticut: 1935 through 1959. *Cancer* 1967; 20:508-11.
130. Berlin BB, Cornwell PM, Connelly RR, Eisenberg H. Radical perineal prostatectomy for carcinoma of the prostate: Survival in 143 cases treated from 1935-1958. *J Urol* 1968; 99:97-101.
131. Connelly RR, Campbell PC, Eisenberg H. Central registry of cancer cases in Connecticut. *Public Health Rep* 1968; 83:386-90.
132. Eisenberg H. Survival experience of cancer of the thyroid by various treatments as experienced in a total population group. Thyroid Cancer Conference, Lausanne, Switzerland. *UICC Monog Ser* 1968; 12:305.
133. Eisenberg H, Sullivan P, Connelly RR. *Cancer in Connecticut: Survival experience 1935-1962* 1968; 1-114.
134. Hulme GW, Eisenberg H, Campbell PC. Carcinoma in-situ of the cervix in Connecticut, a review, 1949-1962. *Am J Obstet Gynecol* 1968; 102:415-25.
135. Kuehn PG, Eisenberg H, Reed JF. Epidermoid carcinoma of the perianal skin and anal canal. *Cancer* 1968; 22:932-8.
136. Moldow RE, Connelly RR. Epidemiology of pancreatic cancer in Connecticut. *Gastroenterol* 1968; 55:677-86.
137. Shedd DP, von Essen CF, Connelly R R, Eisenberg H. Cancer of the buccal mucosa, palate, and gingiva, Connecticut, 1935-1959. *Cancer* 1968; 21:440-6.
138. Shedd DP, von Essen CF, Connelly RR, Eisenberg H. Cancer of the pharynx, Connecticut 1935-1959. *Cancer* 1968; 21:706-13.
139. Shedd DP, von Essen CF, Eisenberg H, Connelly RR. Cancer of the floor of the mouth in Connecticut, 1935-1959. *Cancer* 1968; 21:97-101.
140. Shedd D, von Essen C, Ferraro R, Connelly RR, Eisenberg H. Cancer of tongue in Connecticut, 1935-1959. *Cancer* 1968; 21:89-96.
141. von Essen CF, Shedd DP, Connelly RR, Eisenberg H. Cancer of the larynx, Connecticut, 1935-1959. *Cancer* 1968; 22:1315-22.
142. Christine BW, Flannery JT, Sullivan PD, Chronic Disease Control Section Staff. *Cancer in Connecticut, 1965* 1969; 1-123.
143. Cuello C, Correa P, Eisenberg H. Geographic pathology of thyroid carcinoma. *Cancer* 1969; 23:230-9.
144. Cutler SJ, Connelly RR. Mammary cancer trends. *Cancer* 1969; 23:767-74.
145. Krackow J. Leukemia case surveillance in Connecticut, July 1, 1967 - June 30, 1968. *Conn Health Bull* 1969; 83.
146. Bailar JC 3rd, Eisenberg H, Mantel N. Time between pairs of leukemia cases. *Cancer* 1970; 25:1301-3.
147. Christine B, Sullivan P, Connelly R. Cancer in Connecticut, 1966. *Conn Health Bull* 1970; 84:125-31.

148. Christine B, Sullivan P, Connelly R, Foote F. Cancer incidence, mortality and survival in Connecticut during the 1960's. *Conn Med* 1970; 34:564-9.
149. Eisenberg H, Shambaugh E. Cancers of the gastrointestinal tract: Trends in incidence and mortality rates. *Proc Natl Cancer Conf* 1970; 417-420.
150. Lipworth L, Abelin T, Connelly R. Socio-economic factors in the prognosis of cancer patients. *J Chronic Dis* 1970; 23:105-16.
151. Shedd DP, Von Essen CF, Connelly RR, Eisenbert H. Cancer of the lip in Connecticut, 1935-1959. *Cancer Bull* 1970; 12:116-20.
152. Christine B, Flannery J, Connelly R. Cancer in Connecticut, 1967. *Conn Health Bull* 1971; 85:47-56.
153. Christine B, Flannery J, Sullivan P. *Cancer in Connecticut, 1966-1968*. 1971; 1-83.
154. Christine B, Flannery J, Sullivan P. Cancer in Connecticut, 1968. *Conn Health Bull* 1971; 85:327-38.
155. Christine BW, Sullivan PD. Effect if cigarette smoking on Connecticut residents. *Conn Health Bull* 1971; 85:23-8.
156. Cutler SJ, Christine B, Barclay TH. Increasing incidence and decreasing mortality rates for breast cancer. *Cancer* 1971; 28:1376-80.
157. Groff WH, Pitt TH, Christine BW. Cervical cancer and social rank in metropolitan Connecticut. *Storrs Agric Expt Station Res Rep* 1971; 34:1-1-12.
158. Munoz N, Connelly RR. Time trends of intestinal and diffuse types of gastric cancer in the United States. *Int J Cancer* 1971; 8:158-64.
159. Shanmugaratnum K, Muir CS, Tow SH, Cheng WC, Christine B, Pedersen E. Rates per 100,000 births and incidence of choriocarcinoma and malignant mole in Singapore Chinese and Malays - Comparison with Connecticut, Norway and Sweden. *Int J Cancer* 1971; 8:165-75.
160. Christine BW, Chapple MF, Nadeau D. Cancer of the cervix in Connecticut. *Conn Med* 1972; 36:669-80.
161. Christine BW, Flannery JT, Sullivan PD. Cancer in Connecticut, 1969. *Conn Health Bull* 1972; 86:103-14.
162. Christine BW, Groff WH, Pitt TH, Chapple MF. The relationship of incidence of cervical cancer and socioeconomic status in seven cities, 1959-1964. *Conn Med* 1972; 36:80-3.
163. Christine BW, Sullivan PD, Flannery JT. Cancer in Connecticut, 1970. *Conn Health Bull* 1972; 86:345-56.
164. Sullivan PD, Christine B, Connelly R, Barrett H. Analysis of trends in age adjusted incidence rates for 10 major sites of cancer. *Am J Public Health* 1972; 62:1065-71.
165. Christine BW, Sullivan PD, Flannery JT. Cancer in Connecticut 1971. *Conn Health Bull* 1973; 87:227-38.
166. Christine BW, Sullivan PD, Flannery JT. Cancer in young Connecticut adults aged 15-29 years, 1950-1969. *Proc 2nd Intl Symposium Cancer Detect Prev* 1973; 2:466-471.
167. Kryscio RJ, Myers MH, Prusiner ST, Heise HW, Christine BW. The space-time distribution of Hodgkin's disease in Connecticut, 1940-69. *J Natl Cancer Inst* 1973; 20:1107-10.

168. O'Connor GT, Correa T, Christine B, Axtell L, Myers M. Hodgkin's disease in Connecticut: Histology and age distribution. *Natl Cancer Inst Monogr* 1973; 36:3-8.
169. Odell R, Sullivan P, Christine B. Mortality from diseases of the respiratory system in Connecticut, 1960-71. *Conn Health Bull* 1973; 87:43-54.
170. Axtell L, Myers M, Christine B, Linden G. Trends in survival and classification for patients with leukemia diagnosed 1940-69. *J Natl Cancer Inst* 1974; 53:375-7.
171. Christine BW. Cancer in Connecticut 1972. *Conn Health Bull* 1974; 88:127-40.
172. Connelly RR, Christine BW. A cohort study of cancer following infectious mononucleosis. *Cancer Res* 1974; 34:1172-1178.
173. Cramer DW, Cutler SJ, Christine B. Trends in the incidence of endometrial cancer in the United States. *Gynecol Oncol* 1974; 2:130-43.
174. Curnen M, Varma A, Christine B, Turgeon L. Childhood leukemia and maternal infections during pregnancy. *J Natl Cancer Inst* 1974; 53:943-7.
175. Schoenberg BS, Christine BW. The Association of neoplasms of the colon and rectum with primary malignancies of other sites. *Am J Proctol* 1974; 25:41-58.
176. Schoenberg BS, Christine BW. Multiple primary malignancies: Index tumors of the breast and reproductive organs. *Proc 10th Intl Cancer Congr* 1974; 3:294-299.
177. Barrett HS, Bradley T, American Cancer Society Connecticut Division, Connecticut State Department of Health, Connecticut State Medical Society. *Follow-Up of Cancer – A Handbook for Physicians*. 1975; 1-30.
178. Christine BW. Cervical cancer screening. *Conn Health Bull* 1975-89:19-22.
179. Dohrmann GJ, Farwell JR, Flannery JT. Childhood glioblastoma multiforme: Connecticut 1935-1973. *Conn Health Bull* 1975; 89:129-131.
180. Meigs JW. The Connecticut cancer epidemiology unit. *Conn Med* 1975; 39:637-40.
181. Schoenberg BS, Christine BW, Whisnant JP. Nervous system neoplasms and primary malignancies of other sites: The unique association between meningiomas and breast cancer. *Neurology* 1975; 25:705-12.
182. Sullivan PD, Flannery JT. Analysis of data from the Connecticut Tumor Registry by several major factors of risk. *Conn Health Bull* 1975; 89:27-35.
183. Gershman ST, Flannery JT, Barrett H, Nadel RK, Meigs JW. Development of the Connecticut Tumor Registry. *Conn Med* 1976; 40:697-701.
184. Kantor ALF, Meigs JW, Heston JF, Flannery JT. Epidemiology of renal cell carcinoma in Connecticut, 1935-1973. *J Natl Cancer Inst* 1976; 57:495-500.
185. Laskey PW, Meigs JW, Flannery JT. Uterine cervical carcinoma in Connecticut, 1935-1973: Evidence of two classes of invasive disease *J Natl Cancer Inst* 1976; 57:1037-43.
186. Meigs JW, Laskey PW, Flannery JT. Evidence for regression for carcinoma in-situ and for a second form of invasive cervical cancer, Connecticut 1935-73. *Geburtshilfe Frauenheilkd* 1976; 36:554-69.

187. Schoenberg BS, Schoenberg DG, Christine BW, Golmez MR. The epidemiology of primary intracranial neoplasms of childhood - a population study. *Mayo Clin Proc* 1976; 51:51-6.
188. Sullivan PD, Flannery JT. Changes in Connecticut's cancer rates, 1970-1974. *Conn Health Bull* 1976; 91:4-8.
189. Curnen MGM, Turgeon L, Flannery JT, Varma AA. Characteristics of mothers at high risk of leukemia developing in their children. *Proc 3rd Intl Symposium Detect Prev Cancer* 1977; 1:991-997.
190. Farwell JR, Dohrmann GJ, Flannery JT. Central nervous system tumors in children. *Cancer* 1977; 40:3123-32.
191. Kantor AF. Current concepts in the epidemiology and etiology of primary renal cell carcinoma. *J Urol* 1977; 117:415-7.
192. Meigs JW. Epidemic lung cancer in women. *JAMA* 1977; 238:1055.
193. Schoenberg BS, Christine BW, Fraumeni JF Jr, Greenberg RA, Schoenberg DG. Multiple primary malignant neoplasms. The Connecticut experience, 1935-1964. *Recent Results Cancer Res* 1977; 58:1-173.
194. Snyder DN, Heston JF, Meigs JW, Flannery JT. Changes in site distribution of colorectal carcinoma in Connecticut, 1940-1973. *Am J Dig Dis* 1977; 22:791-7.
195. Spencer RP, Flannery JT. The spleen in osteogenic sarcoma: A scan and autopsy survey. *Clin Nucl Med* 1977; 2:315-7.
196. Dohrmann GJ, Farwell JR, Flannery JT. Oligodendrogliomas in children. *Surg Neurol* 1978; 10:21-5.
197. Farwell JR, Dohrmann GJ, Flannery JT. Intracranial neoplasms in infants. *Arch Neurol* 1978; 35:533-7.
198. Flannery JT, Sullivan PD. Female breast cancer in Connecticut - incidence, mortality, survival - 1935-1975. *Conn Health Bull* 1978; 92:4-9.
199. Houghton A, Munster EW, Viola MV. Increased incidence of malignant melanoma after peaks of sunspot activity. *Lancet* 1978; 1:759-60.
200. Jekel JF, Freeman DH, Meigs JW. A study of trends in upper arm soft tissue sarcomas in the State of Connecticut following the introduction of Alumadsorbed Allergenic Extract. *Ann Allergy* 1978; 40:28-31.
201. Harrington JM, Craun GF, Meigs JW, Landrigan PJ, Flannery JT, Woodhull RS. Investigation of the use of asbestos cement pipe for public water supply and the incidence of gastrointestinal cancer in Connecticut, 1935-1973. *Am J Epidemiol* 1978; 107:96-103.
202. Marrett LD, Elwood JM, Meigs JW, Flannery JT. Recent trends in the incidence and mortality of cancer of the uterine corpus in Connecticut. *Gynecol Oncol* 1978; 6:183-95.
203. Weiss NS, Flannery JT. The relationship of marital status to survival from melanoma. *Cancer* 1978; 42:296-298.
204. Kantor AF, Curnen MGM, Meigs JW, Flannery JT. Occupations of fathers of patients with Wilm's Tumor. *J Epidemiol Community Health* 1979; 33:253-6.

205. Thetford NA, McKernon RF, Flannery JT, Weiss T. Central Cancer Registry Data Management System. *Proc Annu Symp Comput Appl Med Care* 1979; 17:804-13.
206. Chung AF, Casey MJ, Flannery JT, Woodruff JM, Lewis JL. Malignant melanoma of the vagina - report of 19 cases. *Obstet Gynecol* 1980; 55:720-7.
207. Dix D, Cohen P. On the role of aging in cancer incidence. *J Theor Biol* 1980; 83:163-73.
208. Dorvlo AS, Enslein K, Salsburg D. A test of the hypothesis that time to tumor in humans fits the "One-Hit" model. *J Environ Pathol Toxicol* 1980; 4:139-43.
209. Houghton A, Flannery J, Viola MV. Malignant melanoma in Connecticut and Denmark. *Int J Cancer* 1980; 25:95-104.
210. Lewisohn HC, Meigs JW, Testa MJ, Flannery JT. The influence of occupational and environmental asbestos exposure on the incidence of malignant mesothelioma in Connecticut. In: *Biological Effects of Mineral Fibres* (Ed. Wagner JC) *IARC Sci Publ* 1980; 30:655-660.
211. Lutes R, Meigs JW, Heston JF, Flannery JT. Increasing testicular cancer incidence in Connecticut. *Conn Med* 1980; 44:327-8.
212. Meigs JW, Walter SD, Heston JF, Millette JR, Craun GF, Woodhull RS, Flannery JT. Asbestos cement pipe and cancer in Connecticut 1955-1974. *J Environ Health* 1980; 42:187-91.
213. Pottorn LM, Stone BJ, Day NE, Pickle LW, Fraumeni JF Jr. Thyroid cancer in Connecticut, 1935-1975: An analysis by cell type. *Am J Epidemiol* 1980; 112:764-74.
214. Roush GC, Meigs JW, Kelly J, Flannery JT, Burdo H. Sinonasal cancer and occupation: A case-control study. *Am J Epidemiol* 1980; 111:183-93.
215. Testa MA, Meigs JW, Flannery JT. Mathematical modeling of cancer incidence rates: Linear models of colon cancer in Connecticut. *J Chronic Dis* 1980; 33:733-43.
216. Gershman ST, Most RS, Lewis JN, Marks JS. An epidemiologic review of cancer in an industrialized Connecticut town. *Conn Med* 1981; 45:17-21.
217. Kantor AF, Greene MH, Boice JD, Fraumeni JF Jr. Are vinca alkaloids associated with myocardial infarction? *Lancet* 1981; 1:1111.
218. Webber BL, Heise H, Neifeld JP, Costa J. Risk of subsequent contralateral breast carcinoma in a population of patients with in-situ breast carcinoma. *Cancer* 1981; 47:2928-32.
219. Adler SN, Lyon DT, Sullivan PD. Adenocarcinoma of the small bowel clinical features, similarity to regional enteritis, and analysis of 338, documented cases. *Am J Gastroenterol* 1982; 77:326-30.
220. Duffner PK, Cohen ME, Flannery JT. Referral patterns of childhood brain tumors in the State of Connecticut. *Cancer* 1982; 50:1636-40.
221. Fox BH, Stanek EJ 3rd, Boyd SC, Flannery JT. Suicide rates among cancer patients in Connecticut. *J Chronic Dis* 1982; 35:89-100.
222. Kantor AF, Li FP, Fraumeni JF Jr, Curnen MGM, Flannery JT. Childhood cancer in offspring of two Wilms tumor survivors. *Med Pediatr Oncol* 1982; 10:85-9.
223. Kleinerman RA, Curtis RE, Boice JD Jr, Flannery JT, Fraumeni JF Jr. Second cancers following radiotherapy for cervical cancer. *J Natl Cancer Inst* 1982; 69:1027-33.

224. Rousch GC, Kelly J, Meigs JW, Flannery JT. Scrotal carcinoma in Connecticut metal workers. *Am J Epidemiol* 1982; 116:76-85.
225. Stevens RG, Moolgavkar SH, Lee JAH. Temporal trends in breast cancer. *Am J Epidemiol* 1982; 115:759-777.
226. Biggar RJ, Curtis RE, Hoffman DA, Flannery JT. Second primary malignancies following salivary gland cancers. *Br. J. Cancer* 1983; 47:383-6.
227. Flannery JT, Boice JD Jr, Kleinerman RA, Curtis RE. The Connecticut Tumor Registry. In: Second Cancer in Relation to Radiation Treatment for Cervical Cancer: results of a cancer registry collaboration (Eds. Day NE, Boice JD Jr). *IARC Sci Publ* 1983; 52:115-121.
228. Ries LG, Pollack ES, Young JL Jr. Cancer patient survival: Surveillance, Epidemiology and End Results program, 1973-79. *J Natl Cancer Inst* 1983; 70:693-707.
229. Teta MJ, Lewinsohn HC, Meigs JW, Vidone RA, Mowad LZ, Flannery JT. Mesothelioma in Connecticut, 1955-1977. *J Occup Med* 1983; 25:749-56.
230. Wyshak G, Honeyman MS, Flannery JT, Beck AS. Cancer in mothers of dizygotic twins *J Natl Cancer Inst* 1983; 70:593-9.
231. Brubaker LH, Wasserman LR, Goldberg JD, Pisciotta AV, McIntyre OR, Kaplan ME, Modan B, Flannery J, Harp R. Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. *Am J Hematol* 1984; 16:367-73.
232. Curnen MGM. Do cancer clusters exist? *Conn Health Bull* 1984; 98:38.
233. Curnen MGM, Thompson WD, Heston JF, Flannery JT. Cancer prevention: The tumor registry connection. *Cancer Detect Prev* 1984; 7:191-9.
234. Farwell J, Dohrmann GJ, Flannery JT. Tumors of the central nervous system in adolescents. *Am Fam Physician* 1984; 29:133-9.
235. Farwell J, Flannery JT. Cancer in relatives of children with central-nervous-system neoplasms. *N Engl J Med* 1984; 311:749-53.
236. Farwell JR, Dohrmann GJ, Flannery JT. Medulloblastoma in childhood: An epidemiological study. *J. Neurosurg.* 1984; 61:657-64.
237. Hadjimichael OC, Meigs JW, Falcier FW, Thompson WD, Flannery JT. Cancer risk among women exposed to exogenous estrogens during pregnancy *J Natl Cancer Inst* 1984; 73:831-4.
238. Teta MJ, Walrath J, Meigs JW, Flannery JT. Cancer incidence among cosmetologists. *J Natl Cancer Inst* 1984; 72:1051-7.
239. Boice JD, Curtis RE, Kleinerman RA, Storm HH, Jensen OM, Jensen HS, Flannery JT, Fraumeni JF Jr. Multiple primary cancers in Connecticut and Denmark. *Natl Cancer Inst Monogr* 1985; 68:1-437.
240. Boice JD Jr, Day NE, Andersen A, Brinton LA, Brown R, Choi NW, Clarke EA, Coleman MP, Curtis RE, Flannery JT, Hakama M, Hakulinen T, Howe GR, Jensen OM, Kleinerman RA, Magnin D, Magnus K, Makela K, Malker B, Miller AB, Nelson N, Patterson CC, Pettersson F, Pompe-Kirn V, Primic-Zakelj M, Prior P, Ravnihar B, Skeet RG, Skjerven JE, Smith PG, Sok M, Spengler RF, Storm HH, Stovall M, Tomkins GWO, Wall C. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. *J Natl Cancer Inst* 1985; 74:955-75.

241. Curnen MGM, Thompson WD, Flannery JT. The Connecticut Tumor Registry: Potential for increasing its usefulness in etiologic research. *Conn Med* 1985; 49:753-59.
242. Flannery JT, Janerich DT. The Connecticut Tumor Registry: Yesterday, today and tomorrow. *Conn Med* 1985; 49:709-13.
243. Harvey EB, Boice JD Jr, Honeyman M, Flannery JT. Prenatal x-ray exposure and childhood cancer in twins. *N Engl J Med* 1985; 312:541-5.
244. Janerich DT, Hadjimichael O, Flannery J. Strategy for elimination of invasive cervical cancer in Connecticut. *Conn Med* 1985; 49:746-53.
245. Marrett LD, Meigs JW, Flannery JT. Bladder cancer in Connecticut: The role of cigarette smoking and other risk factors. *Conn Med* 1985; 49:718-26.
246. Rosenberg JM, Welch JP. Carcinoid tumors of the colon. *Am J Surg* 1985; 149:775-9.
247. Roush GC, Schymura MJ, Holford TR, White C, Flannery JT. Time period compared to birth cohort in Connecticut incidence rates for twenty-five malignant neoplasms. *J Natl Cancer Inst* 1985; 74:779-88.
248. Brown LM, Pottern LM, Hoover RN, Devesa SS, Aselton P, Flannery JT. Testicular cancer in the United States: Trends in incidence and mortality. *Intl J Epidemiol* 1986; 15:164-70.
249. Feldman AR, Kessler L, Myers MH, Naughton MD. The prevalence of cancer (Estimates based on the Connecticut Tumor Registry). *N Engl J Med* 1986; 315:1394-7.
250. Heston JF, Kelly JAB, Meigs JW, Flannery JT. Forty-five years of cancer incidence in Connecticut: 1935-79. *Natl Cancer Inst Monogr* 1986; 70:1-706.
251. Kantor AF, McLaughlin JK, Curtis RE, Flannery JT, Fraumeni JF Jr. Risk of second malignancy after cancers of the renal parenchyma, renal pelvis, and ureter. *Cancer* 1986; 58:1158-61.
252. Meigs WJ, Marrett LD, Ulrich FU, Flannery JT. Bladder tumor incidence among workers exposed to benzidine: A thirty-year follow-up. *J Natl Cancer Inst* 1986; 76:1-8.
253. Stevens RG. Age and risk of acute leukemia. *J Natl Cancer Inst* 1986; 76:845-8.
254. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr. A population-based case-control study of thyroid cancer. *J Natl Cancer Inst* 1987; 79:1-12.
255. Roush GC, Wairath J, Stayner LT, Kaplan SA, Flannery JT, Blair A. Nasopharyngeal cancer, sinonasal cancer and occupations related to formaldehyde: A case-control study. *J Natl Cancer Inst* 1987; 79:1221-4.
256. Gershman ST, Stolley PD. A case-control study of testicular cancer using Connecticut Tumor Registry data. *Intl J Epidemiol* 1988; 17:738-42.
257. Horwitz RI, Viscoli CM, Merino M, Brennan TA, Flannery JT, Robboy SJ. Clear cell adenocarcinoma of the vagina and cervix: Incidence, undetected disease, and diethylstilbestrol. *J Clin Epidemiol* 1988; 41:593-7.
258. Curtis RE, Boice JD Jr, Stovall M, Flannery JT, Moloney WC. Leukemia risk following radiotherapy for breast cancer. *J Clin Oncol* 1989; 7:21-9.

259. Farley TA, Flannery JT. Late-stage diagnosis of breast cancer in women of lower socioeconomic status: Public Health Implications. *Am J Public Health* 1989; 79:1508-12.
260. Polednak AP. Survival of children diagnosed with acute lymphoblastic leukemia in 1977-82 in Connecticut. *J Clin Epidemiol* 1989; 42:617-23.
261. Chen J, Katz RV, Krutchkoff DJ. Epidemiology of oral cancer in Connecticut 1935 to 1985. *Cancer* 1990; 65:2796-802.
262. Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. *Am J Epidemiol* 1990;131:961-972.
263. Claus EB, Risch NJ, Thompson WD. Using age of onset to distinguish between subforms of breast cancer. *Ann Hum Genet* 1990;54:169-177.
264. Curtis RE, Boice JD Jr, Moloney WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. *Cancer Res* 1990; 50:2741-6.
265. Savoca PE, Ballantyne GH, Flannery JT, Modlin IM. Mucinous rectal cancer in the State of Connecticut: 1982-1986. *Dis Colon Rectum* 1990; 33:13.
266. Vukasin AP, Ballantyne GH, Flannery JT, Lerner E, Modlin IM. Increasing incidence of cecal and sigmoid carcinoma. *Cancer* 1990; 66:2442-9.
267. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* 1991;48:232-242.
268. Dubrow R, Flannery JT, Liu W. Time trends in malignant melanoma of the upper limb in Connecticut. *Cancer* 1991; 68:1854-8.
269. Inskip PD, Harvey EB, Boice JD Jr, Stone BJ, Matanoski G, Flannery JT, Fraumeni JF Jr. Incidence of childhood cancer in twins. *Cancer Causes Control* 1991; 2:315-24.
270. Polednak AP. Time trends in incidence of brain and central nervous system cancers in Connecticut. *J Natl Cancer Inst* 1991; 83:1679-81.
271. Polednak A, Flannery JT, Janerich DT. Cervical cancer rates by population size of towns: Implications for cancer control programs. *J Community Health* 1991; 16:315-23.
272. Wyshak G, Burdick E, Mosteller F. Technology assessment in the Connecticut Tumor Registry. *Int J Technol Assess Health Care* 1991; 7:129-33.
273. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. *N Engl J Med* 1992; 326:781-5.
274. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. *N Engl J Med* 1992; 326:1745-51.
275. Flannery JT, Polednak AP, Fine JA, Mayne ST, Mayne JT. *Cancer trends and cancer prevention research in Connecticut. A Statistical and epidemiological report 1935-1986.* 1992; 1-149.
276. Ghali MH, Yoo KY, Flannery JT, Dubrow R. Association between childhood rhabdomyosarcoma and maternal history of stillbirths. *Int J Cancer* 1992; 50:365-8.

277. Gregorio DI, Flannery JT, Hansen H. Stomach cancer patterns in European immigrants to Connecticut, United States. *Cancer Causes Control* 1992; 3:215-21.
278. Gregorio DI, Lolachi P, Hansen H. Detecting Colorectal Cancer with a large scale fecal occult blood testing program. *Public Health Rep* 1992; 107:331-5.
279. Kern KA. Ten-year review of overall survival rates for stage I cutaneous melanoma in 3,009 residents of Connecticut. *Conn Med* 1992; 56:283-5.
280. Polednak AP. Cancer incidence in the Puerto Rican-born population of Connecticut. *Cancer* 1992;70:1172-1176.
281. Polednak AP, Flannery JT. Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. *Cancer* 1992;70:2152-2158.
282. Shelton D, Paturzo D, Flannery J, Gregorio D. Race, stage of disease, and survival with cervical cancer. *Ethn Dis* 1992; 2:47-54.
283. Travis LB, Gonzalez CL, Hankey BF, Jaffe ES. Hodgkin's disease following Non-Hodgkin's Lymphoma. *Cancer* 1992; 69:2337-42.
284. Zheng T, Mayne ST, Boyle P, Holford TR, Liu W, Flannery J. Epidemiology of non-Hodgkin lymphoma in Connecticut, 1935-1988. *Cancer* 1992; 70:840-9.
285. Zheng T, Mayne ST, Flannery J. The time trends of multiple myeloma in Connecticut, 1935-1987). *Int J Cancer* 1992; 50:163-4.
286. Zheng T, Mayne ST, Holford TR, Boyle P, Liu W, Chen Y, Mador M, Flannery J. Time trend and age-period-cohort effects on incidence of esophageal cancer in Connecticut, 1935-89. *Cancer Causes Control* 1992; 3:481-92.
287. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. *Breast Cancer Res Treat* 1993;28:115-120.
288. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. *Cancer* 1993;71:147-153.
289. Polednak AP. Geographic Variation in the treatment of prostate cancer in Connecticut. *Intl J Technol Assess Health Care* 1993; 9:304-10.
290. Polednak AP. Estimating cervical cancer incidence in the Hispanic population of Connecticut by use of surnames. *Cancer* 1993;71:3560-3564.
291. Polednak AP. Lung cancer rates in the Hispanic population of Connecticut, 1980-88. *Public Health Rep* 1993;108:471-476.
292. Polednak A, Flannery JT. Trends in breast cancer treatment in Connecticut. *Conn Med* 1993; 57:59-64.
293. Zheng T, Mayne ST, Holford TR, Boyle P, Liu W, Chen Y, Mador M, Flannery J. Time trend and age-period-cohort effects on incidence of adenocarcinoma of the stomach in Connecticut from 1955-1989. *Cancer* 1993; 72:330-40.
294. Berwick M, Dubin N, Luo S, Flannery J. No improvement in survival from melanoma diagnosed from 1973 to 1984. *Intl J Epidemiol* 1994; 23:673-81.

295. Chen Y, Zheng T, Holford TR, Berwick M, Dubrow R. Malignant melanoma incidence in Connecticut (United States): Time trends and age-period-cohort modeling by anatomic site. *Cancer Causes Control* 1994; 5:341-50.
296. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. *Cancer* 1994;73:643-651.
297. Flannery J, Polednak AP. *Cancer Incidence in Connecticut 1980 - 1991*. 1994; 1-38.
298. Katz DL, Zheng T, Holford TR, Flannery J. Time trends in the incidence of renal carcinoma: Analysis of Connecticut Tumor Registry data, 1935-1989. *Int J Cancer* 1994; 58:57-63.
299. Morse DE, Flannery JT, Krutchkoff DJ, Eisenberg E. An assessment of oral cancer underregistration at the Connecticut Tumor Registry. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1994; 79:753-5.
300. Muir CS, Storm HH, Polednak A. Brain and other nervous system tumours. *Cancer Surv* 1994; 19-20:369-92.
301. Polednak AP. Cutaneous melanoma in Connecticut towns, 1989-91. *Conn Med* 1994; 58:515-8.
302. Polednak, A.P. Re: Increased mortality from brain tumors: A combined outcome of diagnostic technology and change in attitude toward the elderly. *Am J Epidemiol* 1994; 140:1138-43.
303. Polednak AP. Projected numbers of cancers diagnosed in the US elderly population, 1990 through 2030. *Am J Public Health* 1994; 84:1313-6.
304. Polednak AP. Re: "Relation between population density and cancer incidence, Illinois, 1986-1990". *Am J Epidemiol* 1994;139:741-742.
305. Polednak AP. Trends in cancer incidence in Connecticut, 1935-1991. *Cancer* 1994; 74:2863-72.
306. Polednak A, Flannery JT. Late-stage breast cancer in Connecticut's three largest cities. *Conn Med* 1994; 58:261-4.
307. State of Connecticut Department of Public Health and Addiction Services. *Connecticut Tumor Registry*. 1994; 1-10.
308. Zheng T, Holford TR, Boyle P, Chen Y, Ward BA, Flannery J, Mayne ST. Time trend and the age-period-cohort effect on the incidence of histologic types of lung cancer in Connecticut, 1960-1989. *Cancer* 1994; 74:1556-67.
309. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. *JAMA* 1995; 274:626-31.
310. Janerich DT, Hadjimichael O, Schwartz PE, Lowell DM, Meigs JW, Merino MJ, Flannery JT, Polednak AP. The screening histories of women with invasive cervical cancer, Connecticut. *Am J Public Health* 1995; 85:791-4.
311. Kleinerman RA, Boice, JD Jr, Storm HH, Sparen P, Andersen A, Pukkala, E, Lynch, CF, Hankey, BF, Flannery JT. Second primary cancer after treatment for cervical cancer. *Cancer* 1995; 76:442-52.
312. Liu W, Kasl S, Flannery JT, Lindo A, Dubrow R. The accuracy of prostate cancer staging in a population-based tumor registry and its impact on the black-white stage difference (Connecticut, United States). *Cancer Causes Control* 1995; 6:425-30.

313. Polednak AP. Declining use of radiotherapy for invasive cervical cancer in Connecticut: 1983-1990. *Gynecol Oncol* 1995; 58:226-9.
314. Polednak AP. Estimating mortality in the Hispanic population of Connecticut, 1990 to 1991. *Am J Public Health* 1995;85:998-1001.
315. Polednak AP. Pre-eclampsia, autoimmune diseases and breast cancer etiology. *Med Hypotheses* 1995;44:414-418.
316. Polednak AP, Flannery JT. Brain, other central nervous system, and eye cancer. *Cancer* 1995; 75:330-7.
317. Polednak AP, Flannery JT. Surveillance of cancer incidence in Connecticut counties and towns, 1989-91. *Conn Med* 1995; 59:323-30.
318. State of Connecticut Department of Public Health. *Cancer Incidence in Connecticut by County and Town, 1989-91*. 1995; 1-175.
319. Zheng T, Holford TR, Ward BA, McKay L, Flannery J, Boyle P. Time trend in pancreatic cancer incidence in Connecticut, 1935-1990. *Int J Cancer* 1995; 61:622-7.
320. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. *J Urol* 1996; 156:127-32.
321. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. *Cancer* 1996; 78:427-32. Errata 1997; 79:423.
322. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. *J Natl Cancer Inst* 1996; 88:17-23.
323. Chen YT, Dubrow R, Holford TR, Zheng T, Barnhill RL, Fine J, Berwick M. Malignant melanoma risk factors by anatomic site: A case-control study and polychotomous logistic regression analysis. *Int J Cancer* 1996; 67:636-43.
324. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. *Cancer* 1996;77:2318-2324.
325. Davis FG, Malinski N, Haenszel W, Chang J, Flannery J, Gershman S, Dibble R, Bigner DD. Primary brain tumor incidence rates in four United States regions, 1985-1989: A Pilot Study. *Neuroepidemiology* 1996; 15:103-12.
326. Holford TR, Zhang Z, Zhang T, McKay LA. A model for the effect of cigarette smoking on lung cancer incidence in Connecticut. *Stat Med* 1996; 15:565-80.
327. Polednak AP. Cancer registry data on smoking habits and follow-up for childhood cancer patients: problems and prospects. *J Registry Manag* 1996; 23:127-31.
328. Polednak AP. Estimating breast cancer incidence in Hispanic women in Connecticut, 1989-1991. *Ethn Health* 1996; 1:229-36.
329. Polednak AP. Familial testicular cancer in a population-based cancer registry. *Urol Int* 1996; 56:238-40.
330. Polednak AP. Interpretation of secular increases in incidence rates for primary brain cancer in Connecticut adults, 1965-1988. *Neuroepidemiology* 1996; 15:51-6.

331. Polednak AP. Reporting of occupational histories to a population-based cancer registry: mesothelioma in Connecticut, 1988-93. *J Registry Manag* 1996; 23:108-11.
332. Polednak AP. Trends in breast-conserving surgery in Connecticut: No effect of negative publicity. *Conn Med* 1996; 60:527-30.
333. Polednak AP. Using a population-based cancer registry in planning breast cancer screening programs in urban neighborhoods. *J Registry Manag* 1996; 179-82.
334. Polednak AP, Flannery JT. Family history of breast and ovarian cancer among breast-cancer patients in Connecticut Tumor Registry. *Conn Med* 1996; 60:67-73.
335. Polednak AP, Shevchenko IP, Flannery JT. Estimating breast cancer treatment charges in Connecticut. *Conn Med* 1996; 60:263-7.
336. Zheng T, Holford TR, Chen Y, Ma JZ, Flannery J, Liu W, Russi M, Boyle P. Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935-1992. *Int J Cancer* 1996; 67:504-9.
337. Zheng T, Holford TR, Chen Y, Ma Z, Liu WL, Flannery J, Boyle P. Lymphocytic leukemias in Connecticut, USA: time trends and racial differences, 1935-92. *J Epidemiol Biostat* 1996; 1:1-8.
338. Zheng T, Holford TR, Chen Y, Ma JZ, Mayne ST, Liu W, Flannery J, Boyle P. Time trend and age-period-cohort effect on incidence of bladder cancer in Connecticut, 1935-1992. *Int J Cancer* 1996; 68:172-6.
339. Zheng T, Holford TR, Ma Z, Ward BA, Flannery J, Boyle P. Continuing increase in incidence of germ-cell testis cancer in young adults: experience from Connecticut, USA, 1935-1992. *Int J Cancer* 1996; 65:723-9.
340. Connecticut Tumor Registry. *Cancer incidence in Connecticut, 1980-94*. 1997; 1-41.
341. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa S, Blot WJ, Fraumeni JF Jr. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1997; 89:1277-84.
342. Jones BA, Kasl SV, Curnen MGM, Owens PH, Dubrow R. Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. *Am J Epidemiol* 1997; 146:394-404.
343. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. *J Clin Oncol* 1997; 15:3408-15.
344. Olsen GW, Gondek MR, Flannery J, Cartmill JB, Bodner KM. A thirty-eight year comparison of cancer incidence and mortality among employees at a Connecticut chemical plant. *Conn Med* 1997; 61:83-9.
345. Polednak AP. Estimating the prevalence of cancer in the United States. *Cancer* 1997; 80:136-41.
346. Polednak AP. Predictors of breast-conserving surgery in Connecticut, 1990-1992. *Ann Surg Oncol* 1997; 4:259-63.
347. Polednak AP. Stage at diagnosis of prostate cancer in Connecticut by poverty and race. *Ethn Dis* 1997; 7:215-20.
348. Polednak AP. Trends in cancer incidence in Connecticut. *Conn Med* 1997; 61:211-8.

349. Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. *Cancer* 1997; 79:99-103.
350. Polednak AP, Shevchenko IP, Flannery JT. Estimating cancer incidence using a hospital discharge database versus a tumor registry. *J Registry Manag* 1997; 24:25-8.
351. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of Mutant p53 in epithelial ovarian cancer. *J Natl Cancer Inst* 1997; 89:932-8.
352. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW. Cigarette smoking and changes in the histopathology of lung cancer. *J Natl Cancer Inst* 1997; 89:1580-6.
353. Zheng T, Holford TR, Chen Y, Jones BA, Flannery J, Boyle P. Time trend of female breast carcinoma in situ by race and histology in Connecticut, U.S.A. *Eur J Cancer* 1997; 33:96-100.
354. Albertsen PC, Nease RF Jr, Potosky AL. Assessment of patient preferences among men with prostate cancer. *J Urol* 1998; 159:158-63.
355. Byrne JL, Rasmussen SA, Steinhorn, SC, Connelly, RR, Myers MH, Lynch CF, Flannery J, Austin DF, Holmes FF, Holmes GE, Strong LC, Mulvihill JJ. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. *Am J Hum Genet* 1998; 62:42-52.
356. Chen YT, Dubrow R, Zheng T, Barnhill RL, Fine J, Berwick M. Sunlamp use and the risk of cutaneous malignant melanoma: a population-based case-control study in Connecticut, USA. *Intl J Epidemiol* 1998; 27:758-65.
357. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF Jr. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1998; 90:150-5.
358. Claus EB, Schildkraut J, Iversen ES, Jr., Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. *J Natl Cancer Inst* 1998;90:1824-1829.
359. Connecticut Tumor Registry. *Incidence of selected cancers in Connecticut by county and town, 1990-94*. 1998; 1-73.
360. Polednak AP. Black-white differences in prostate cancer treatment: The need to consider stage at diagnosis and socioeconomic status. *J Natl Med Assoc* 1998; 90:101-4.
361. Polednak AP. Cancer registry surveillance of breast cancer incidence in communities. *J Registry Manag* 1998; 25:52-5.
362. Polednak AP. Do physicians discuss genetic testing with family-history-positive breast cancer patients? *Conn Med* 1998; 62:3-7.
363. Polednak AP. Prostate cancer treatment in black and white men: the need to consider both stage at diagnosis and socioeconomic status. *J Natl Med Assoc* 1998;90:101-104.
364. Polednak AP. Regarding: "Trends in the incidence of upper extremity soft tissue malignancies: a 40-year review of the Connecticut State Tumor Registry". *Conn Med* 1998;62:311-312.
365. Polednak AP, Shevchenko IP. Hospital charges for terminal care of cancer patients dying before age 65 years. *J Health Care Finance* 1998; 25:26-34.

366. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. *Intl J Epidemiol* 1998; 27:751-7.
367. State of Connecticut Department of Public Health. *Connecticut Tumor Registry since 1935*. 1998; 1-12.
368. Zahir KS, Quin JA, Brown W, Thomson JG, Dudrick SJ. Trends in the incidence of upper extremity soft tissue malignancies: A 40-year review of the Connecticut State Tumor Registry. *Conn Med* 1998; 62:9-14.
369. Connecticut Tumor Registry. *Cancer incidence in Connecticut, 1980-96*. 1999; 1-36.
370. Gilliland FD, Hoffman RM, Hamilton A, Albertsen P, Eley JW, Harlan L, Stanford JL, Hunt WC, Potosky A. Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: Results from the population based prostate cancer outcomes study. *J Urol* 1999; 162:1341-5.
371. Gregorio DI, Cromley E, Mrozinski R, Walsh SJ. Subject loss in spatial analysis of breast cancer. *Health Place* 1999; 5:173-7.
372. Gregorio DI, Walsh SJ, Tate JP. Diminished socioeconomic and racial disparity in the detection of early-stage breast cancer, Connecticut, 1986-1995. *Ethn Dis* 1999; 9: 396-402.
373. Polednak AP. Comorbidity and mortality of breast cancer patients diagnosed before age 65 years. *J Registry Manag* 1999; 26:71-4.
374. Polednak AP. Epidemiology of breast cancer in Connecticut women. *Conn Med* 1999; 63:7-16.
375. Polednak AP. Hospital volume and survival of breast cancer patients in Connecticut. *Am J Public Health* 1999; 89:946-7.
376. Polednak AP. Melanoma incidence in Connecticut by town of residence. *Health Place* 1999; 5:131-7.
377. Polednak AP. Postmastectomy breast reconstruction in Connecticut: trends and predictors. *Plast Reconstr Surg* 1999; 104:669-73.
378. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS. Prostate cancer practice patterns and quality of life: the prostate cancer outcomes study. *J Natl Cancer Inst* 1999; 91:1719-24.
379. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. *N Engl J Med* 1999; 340:351-7.
380. Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. *J Urol* 2000; 163:1138-43.
381. Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. *J Urol* 2000; 163:519-23.
382. Connecticut Tumor Registry. *Cancer incidence in Connecticut by Town of Residence 1997*. 2000; 1-47.
383. Polednak AP. Geographic variation in postmastectomy breast reconstruction rates. *Plast Reconstr Surg* 2000; 106:298-301.
384. Polednak AP. Hospital charges for colorectal cancer patients first admitted through an emergency department. *Journal Health Care Finance* 2000; 24:44-9.

385. Polednak AP. Inpatient hospital admission through an emergency department in relation to stage at diagnosis of colorectal cancer. *Cancer Detect Prev* 2000; 24:283-9.
386. Polednak AP. Later-stage cancer in relation to medically underserved areas in Connecticut. *Journal Health Care Poor Underserved* 2000; 11:301-9.
387. Polednak AP. Racial differences in the treatment of early-stage lung cancer. *N Engl J Med* 2000;342:517-518.
388. Polednak AP. Trends in late-stage breast, cervical and colorectal cancers in blacks and whites. *Ethn Dis* 2000; 10:60-8.
389. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. *J Natl Cancer Inst* 2000; 92:1582-92.
390. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. The Prostate Cancer Outcomes Study. *JAMA* 2000; 283:354-60.
391. Zheng T, Holford TR, Mayne ST, Tessari J, Ward B, Carter D, Oweens PH, Boyle P, Dubrow R, Archibeque-Engle S, Dawood O, Zahm SH. Risk of female breast cancer associated with Serum Polychlorinated Biphenyls and 1,1-Dichloro-2,2'-bis(p-chlorophenyl)ethylene. *Cancer Epidemiol Biomarkers Prev* 2000; 9:167-74.
392. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. *J Natl Cancer Inst* 2001;93:1811-1817.
393. Clegg LX, Potosky AL, Harlan LC, Hankey BF, Hoffman RM, Stanford JL, Hamilton AS. Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes study. *Am J Epidemiol* 2001; 154:582-7.
394. Connecticut Tumor Registry. *Cancer incidence in Connecticut, 1980-98*. 2001; 1-37.
395. Connecticut Tumor Registry. *Cancer incidence in Connecticut, 1999*. 2001; 1-15.
396. Connecticut Tumor Registry. *Cancer incidence in Connecticut by Town of Residence 1998*. 2001; 1-55.
397. Connecticut Tumor Registry. *Cancer incidence in Connecticut Counties, 1997*. 2001; 1-30.
398. Connecticut Tumor Registry. *Incidence of Selected Cancers in Connecticut by Town, 1999*. 2001; 1-82.
399. Desai MM, Bruce, ML, Desai RA, Druss BG. Validity of self-reported cancer history: a comparison of health interview data and cancer registry records. *Am J Epidemiol* 2001; 153:299-306.
400. Gregorio DI, Kullendorff M, Barry L, Samocuik H, Zarfos K. Geographical differences in primary therapy for early-stage breast cancer. *Ann Surg Oncol* 2001; 8:844-9.
401. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, Eley JW, Harlan LC, Potosky AL. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the prostate cancer outcomes study. *J Clin Oncol* 2001; 19:2517-26.

402. Harlan, LC, Potosky A., Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford, JL, Stephenson RA. factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. *J Natl Cancer Inst* 2001; 93:1864-71.
403. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertsen PC, Hamilton AS, Hunt WC, Potosky AL. Racial and ethnic differences in advanced-stage prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst* 2001; 93:388-95.
404. Polednak AP. Agreement in race-ethnicity coding between a hospital discharge database and another database. *Ethn Dis* 2001; 11:24-9.
405. Polednak AP. Re: Association of African-American ethnic background with survival in men with prostate cancer. *J Natl Cancer Inst* 2001; 93:1174-5.
406. Polednak A. Disparities in surgical treatment of early-stage non-small-cell lung cancer. *Yale J Biol Med* 2001; 74:309-14.
407. Polednak, AP. Frequency of prophylactic contralateral mastectomy among breast cancer patients. *J Am Coll Surg* 2001; 192:804-5.
408. Polednak AP. How frequent is postmastectomy breast reconstructive surgery? A study linking two statewide databases. *Plast Reconstr Surg* 2001; 108:73-7.
409. Polednak AP. Poverty, comorbidity and survival of colorectal cancer patients. *J Health Care Poor Underserved* 2001; 12:302-10.
410. Polednak AP. Reporting of smoking histories to a tumor registry. *J Registry Manag* 2001; 28:18-21.
411. Polednak AP. Type of breast reconstructive surgery among breast cancer patients: A population-based study. *Plast Reconstr Surg* 2001; 108:1600-3.
412. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality of life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. *J Clin Oncol* 2001; 19:3750-7.
413. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 1995-1999*. 2002; 1-17.
414. Connecticut Tumor Registry. *Cancer Incidence in Connecticut Counties, 1995-98*. 2002; 1-27.
415. Connecticut Tumor Registry. *Connecticut Tumor Registry Report - April 2002*. 2002:1-10.
416. Connecticut Tumor Registry. *Incidence of Selected Cancers in Connecticut by Town, 1995-99*. 2002; 1-65.
417. Gregorio DJ, Kulldorff, M., Barry L., Samociuk H., Geographic differences in invasive and in situ breast cancer incidence according to precise geographic coordinates, Connecticut, 1991-95. *Int J Cancer* 2002; 100:194-8.
418. Harlan LC, Abrams J, Warren J, Clegg L, Stevens J, Ballard-Barbash R. Adjuvant therapy for breast cancer - practice patterns of community physicians. *J Clin Oncol* 2002; 20:1809-17.
419. Mariotto A, Feuer E, Harlan LC, Wun LM, Johnson K, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and Tamoxifen for breast cancer in the United States. *J Natl Cancer Inst* 2002; 94:1626-34.

420. Mitacek EJ, Brunnemann KD, Polednak AP, Limsila T, Bhothisuwan K, Hummel CF. Rising leukemia rates in Thailand: the possible role of benzene and related compounds in cigarette smoke. *Oncol Rep* 2002;9:1399-1403.
421. Polednak AP. Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992-98. *Ethn Dis* 2002; 12:536-41.
422. Polednak AP. Survival of breast cancer patients in Connecticut in relation to socioeconomic and health care access indicators. *J Urban Health* 2002; 79:211-8.
423. Polednak AP. Trends in, and predictors of, breast-conserving surgery and radiation therapy for breast cancer in Connecticut, 1988-97. *Intl J Radiat Oncol Biol Phys* 2002; 53:157-63.
424. Potosky AL, Harlan LC, Kaplan RC, Johnson K, Lynch CF. Age, sex, and racial differences in use of standard adjuvant therapy for colorectal cancer. *J Clin Oncol* 2002; 20:1192-202.
425. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. *J Natl Cancer Inst* 2002; 94:430-7.
426. Verdecchia A, DeAngelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. *Stat Med* 2002; 21:3511-26.
427. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data to identify chemotherapy use. *Med Care* 2002; 40:IV-55-61.
428. Claus EB, Stowe M, Carter D, Holford T. The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. *Breast* 2003;12:451-456.
429. Claus EB, Stowe M, Carter D. Oral contraceptives and the risk of ductal breast carcinoma in situ. *Breast Cancer Res Treat* 2003;81:129-136.
430. Claus EB, Stowe M, Carter D. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ. *Breast Cancer Res Treat* 2003;78:7-15.
431. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2000*. 2003; 1-14.
432. Gregorio DI, Samociuk H. Breast cancer surveillance using gridded population units, Connecticut, 1992 to 1995. *Ann Epidemiol* 2003; 13:42-9.
433. Harlan L, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. *J Clin Oncol* 2003; 21:3488-94.
434. Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, Potosky AL. Racial differences in initial treatment for clinically localized prostate cancer. *J Gen Intern Med* 2003; 18:845-53.
435. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL. Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. *Cancer* 2003; 97:1653-62.
436. Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL and Stanford JL. General quality of life 2 years following treatment for

prostate cancer: what influences outcomes? Results from the Prostate Cancer Outcomes Study. *J Clin Oncol* 2003; 21:1147-54.

437. Polednak AP. Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection and survival. *Surgery* 2003; 133:383-9.
438. Polednak AP. Black-white differences in survival from late-stage prostate cancer. *Ethn Dis* 2003; 13:220-5.
439. Polednak AP. Geographic distribution of incident mesothelioma in Connecticut men, 1990-99. *Int J Cancer* 2003; 107:509-10.
440. Polednak AP. Survival of lymph-node negative breast cancer patients in relation to the number of lymph nodes examined. *Ann Surg* 2003; 237:163-7.
441. Polednak AP. Trends in incidence rates for obesity-related cancers in the U.S. *Cancer Detect Prev* 2003; 27:415-21.
442. Polednak AP. Trends in late-stage breast and cervical cancer incidence rates in Connecticut (United States). *Cancer Causes Control* 2003; 14:361-5.
443. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. *Int J Cancer* 2003; 105:98-100.
444. Shavers VL, Harlan LC, Stevens J. Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. *Cancer* 2003; 97:134-47.
445. Shavers VL, Harlan LC, Winn D, Davis WW. Racial/ethnic patterns of care for cancers of the oral cavity, pharynx, larynx, sinuses, and salivary glands. *Cancer Metastasis Rev* 2003;22:25-38.
446. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of care for the treatment of bladder cancer. *J Urol* 2003; 169:1697-701.
447. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. *Cancer* 2003; 98:2:496-503.
448. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. *J Urol* 2004; 171:2221-5.
449. Castillo MS, Davis FG, Surawicz T, Bruner JM, Bigner S, Coons S, Bigner DD. Consistency of Primary Brain Tumor Diagnoses and Codes in Cancer Surveillance Systems. *Neuroepidemiology* 2004; 23:85-93.
450. Chang ET, Zheng T, Lennette ET, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Heterogeneity of risk factors and antibody profiles in Epstein-Barr virus genome-positive and -negative Hodgkin lymphoma. *J Infect Dis* 2004; 189:2271-81.
451. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. *J Natl Cancer Inst* 2004; 96:305-15.
452. Chang ET, Zheng T, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. *Cancer Epidemiol Biomarkers Prev* 2004; 13:1361-70.

453. Connecticut Department of Public Health. *Connecticut Cancer Surveillance 1990-2000*. 2004; 1-24.
454. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2001*. 2004; 1-16.
455. Connecticut Tumor Registry. *Cancer Incidence in Connecticut Counties, 1995-99*. 2004; 1-26.
456. Gammon MD, Terry MB, Arber N, Chow W, Risch HA, Vaughan TL, Schoenberg JB, Mayne ST, Stanford JL, Dubrow R, Rotterdam H, West AB, Fraumeni JF Jr, Weinstein IB, Hibshoosh H. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinoma of the esophagus and gastric cardia that overexpress cyclin D1: A population-based study. *Cancer Epidemiol Biomarkers Prev* 2004; 13:34-9.
457. Hoffman RM, Gilliland, FD, Penson DF, Stone SN, Hunt, WC, Potosky AL. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. *Cancer* 2004; 101:2011-9.
458. Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson D, Stanford J, Albertsen P, Hamilton AS. Racial/ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. *J Clin Oncol* 2004; 22: 4193-201.
459. Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics. *Cancer* 2004; 101:1293-301.
460. Legler JM, Davis WW, Potosky AL, Hoffman RM. Latent variable modeling of recovery trajectories: sexual function following radical prostatectomy. *Stat Med* 2004; 23:2875-93.
461. Mayne ST, Cartmel B, Lin H, Zheng T, Goodwin WJ Jr. Low plasma lycopene concentration is associated with increased mortality in a cohort of patients with prior oral, pharynx or larynx cancers. *J Am Coll Nutr* 2004; 23:34-42.
462. Morton LM, Engels EA, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, Zhang B, Flynn S, Tallini G, Owens PH, Zheng T. Hepatitis C virus and risk of non-Hodgkin lymphoma: A population-based case-control study among Connecticut women. *Cancer Epidemiol Biomarkers Prev* 2004; 13:425-30.
463. Polednak AP. Chemotherapy of nonelderly breast cancer patients by poverty rate of area of residence in Connecticut. *Breast Cancer Res Treat* 2004; 83:245-8.
464. Polednak AP. Geographic patterns of cancers related to tobacco and alcohol in Connecticut: Implications for cancer control. *Cancer Detect Prev* 2004; 28:302-8.
465. Polednak AP. Lung Cancer incidence trends in black and white young adults by gender. *Cancer Causes Control* 2004; 15:665-70.
466. Polednak AP. Obesity and comorbidity from hospital records, for population-based studies of prognosis. *J Registry Manag* 2004; 31:75-78.
467. Polednak AP. Racial differences in obesity-related chronic disease mortality among U.S. women diagnosed with breast cancer. *Ethn Dis* 2004; 14:463-8.
468. Polednak AP. Surveillance for hospitalizations with infection after chemotherapy among non-elderly breast cancer patients. *Chemotherapy* 2004; 50:157-61.
469. Polednak AP. Survival of U.S. black and white patients with squamous cell cancer of the esophagus. *J Natl Med Assoc* 2004; 96:87-92.

470. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson, DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. *J Natl Cancer Inst* 2004; 96: 1358-67.
471. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Flynn S, Tallini G, Owens PH, Zheng T. Hair coloring product use and risk of non-Hodgkin's lymphoma: A population-based case-control study in Connecticut. *Am J Epidemiol* 2004; 159:148-54.
472. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Owens PH, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Zheng T. Blood transfusion and risk of non-Hodgkin's lymphoma in Connecticut women. *Am J Epidemiol* 2004; 160:325-30.
473. Zhang Y, Holford TR, Leaderer B, Boyle P, Zahm SH, Zhang B, Zou K, Morton LM, Owens PH, Flynn S, Tallini G, Zheng T. Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut women. *Am J Epidemiol* 2004; 160:766-73.
474. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. *Cancer Causes Control* 2004; 15:419-28.
475. Zheng T, Holford TR, Leaderer B, Zhang Y, Zahm SH, Flynn S, Tallini G, Zhang B, Zhou K, Owens PH, Lan Q, Rothman N, Boyle P. Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. *Am J Epidemiol* 2004; 159:454-66.
476. Albertsen P, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. *JAMA* 2005; 293:2095-101.
477. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Barnhill R. Sun exposure and mortality from melanoma. *J Natl Cancer Inst* 2005; 97:195-9.
478. Cartmel B, Bowen D, Ross D, Johnson E, Mayne S. A randomized trial of an intervention to increase fruit and vegetable intake in curatively treated patients with early-stage head and neck cancer. *Cancer Epidemiol Biomarkers Prev* 2005; 14:2848-54.
479. Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, Rodriguez C, Sinha R, Calle EE. Meat consumption and risk of colorectal cancer. *JAMA* 2005; 293:172-82.
480. Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. *JAMA* 2005; 293:964-9.
481. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2002*. 2005; 1-16.
482. Hoffman RM, Stone SN, Espey D, Potosky AL. Differences between men with screening-detected versus clinically diagnosed prostate cancer in the USA. *BMC Cancer* 2005; 5:27.
483. Klabunde CM, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time? Results from the Prostate Cancer Outcomes Study. *Med Care* 2005; 43:391-400.
484. Penson DF, McLerran D, Feng Z, Li, L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-Year urinary and sexual outcomes after radical prostatectomy: Results from the prostate cancer outcomes study. *J Urol* 2005; 173:1701-5.

485. Polednak AP. Collecting information on race, Hispanic ethnicity and birthplace of cancer patients: Policies and practices in Connecticut Hospitals. *Ethn Dis* 2005; 15:90-6.
486. Polednak AP. Explaining geographical variation in breast and cervical cancer incidence rates in U.S. Hispanic women. *Ethn Dis* 2005; 15:727-32.
487. Polednak AP. For the patient. How Connecticut hospitals collect information on race, Hispanic ethnicity, and birthplace. *Ethn Dis* 2005;15:153.
488. Polednak AP. Improving completeness of data on birthplace of minority patients in cancer registries. *J Registry Manag* 2005; 32:79-84.
489. Polednak AP. Obtaining information on usual occupation as an indicator of socioeconomic status of patients in a population-based cancer registry. *J Registry Manag* 2005; 32:176-81.
490. Polednak AP. Recent trends in incidence rates for selected alcohol-related cancers in the United States. *Alcohol Alcohol* 2005; 40:234-8.
491. Polednak AP. Revisiting the 1973 report, 'Alarming increase of the cancer mortality in the U.S. black population (1950-1967)'. *Ethn Dis* 2005; 15:779-85.
492. Soler-Vilá H, Kasl SV, Jones BA. Cancer-specific beliefs and survival: A population-based study of African-American and White breast cancer patients. *Cancer Causes Control* 2005; 16:105-14.
493. Stephenson RA, Mori M, Hsieh Y, Beer TM, Stanford JL, Gilliland FD, Hoffman RM, Potosky AL. Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. *J Urol* 2005; 174:646-50.
494. Trivers KF, DeRoos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF Jr, Chow W. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. *Clin Gastroenterol Hepatol* 2005; 3:225-30.
495. Zhang Y, Lan Q, Rothman N, Zhu Y, Hoar-Zahm S, Wang SS, Holford TR, Leaderer B, Boyle P, Zhang B, Zou K, Chanock S, Zheng T. A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma. *J Natl Cancer Inst* 2005; 97:1616-8.
496. Claus EB, Petruzella S, Carter D, Kasl S. Quality of life for women diagnosed with breast carcinoma in situ. *J Clin Oncol* 2006; 24:4875-81.
497. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2003*. 2006; 1-20.
498. Connecticut Tumor Registry. *Cancer Incidence in Connecticut Counties, 1990 - 2002*. 2006; 1-28.
499. Connecticut Tumor Registry. *Cancer Incidence (Numbers of Cancers) in Connecticut Towns 2000-2003*. 2006; 1-39.
500. Gregorio DI, Samociuk H, DeChello L, Swede H. Effects of study area size on geographic characterizations of health events: Prostate cancer incidence in Southern New England, 1994-1998. *Intl J Health Geogr* 2006; 5:8.

501. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. *Breast Cancer Res* 2006; 8:R22.
502. Kulldorff M, Song G, Gregorio DI, Samociuk H, DeChello L. Cancer map patterns: Are they random or not? *Am J Prev Med* 2006; 30: S37-S49.
503. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S. Cytokine polymorphisms in the Th1/Th pathway and susceptibility to non-Hodgkin lymphoma. *Blood* 2006; 107:4101-8.
504. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. *Cancer Epidemiol Biomarkers Prev* 2006; 15:2342-7.
505. Mayne ST, Risch HA, Dubrow R, Wong-Ho C, Gammon MD, Vaughan TL, Borchardt L, Schoenberg JB, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Carbonated soft drink consumption and risk of esophageal adenocarcinoma. *J Natl Cancer Inst* 2006; 98:72-5.
506. Polednak AP. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. *Cancer Detect Prev* 2006; 30:466-72.
507. Polednak AP. Monitoring and surveillance of obesity in the United States. *Curr Nutr Food Sci* 2006; 2:231-42.
508. Polednak AP. Obtaining population-based data on obesity among cancer patients at diagnosis. *J Registry Manag* 2006; 33:107-11.
509. Polednak AP. Obtaining smoking histories for population-based studies of multiple primary cancers. *Int J Cancer* 2006; 119:233-5.
510. Polednak AP. Regarding "Prevalence of the metabolic syndrome in relation to self-reported cancer history." *Ann Epidemiol* 2006; 16:877-9.
511. Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev* 2006; 15:1738-41.
512. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, DeSanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. *Lancet Oncol* 2006; 7:27-38.

513. Sandler DP, Weinberg CR, Shore DL, Archer VE, Stone MB, Lyon JL, Rothney-Koxlak L, Shepherd M, Stolwijk JAJ. Indoor Radon and Lung Cancer Risk in Connecticut and Utah. *J Toxicol Environ Health A* 2006; 69:633-54.
514. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev* 2006; 15:1226-8.
515. Swede H, Bartos JD, Chen N, Shaukat A, Dutt SS, McQuaid DA, Natarajan N, Rodriguez-Bigas MA, Nowak NJ, Wiseman SM, Alrawi S, Brenner BM, Petrelli NJ, Cummings KM, Stoler DL, Anderson GR. Genomic profiles of colorectal cancers differ based on patient smoking status. *Cancer Genet Cytogenet* 2006; 168:98-104.
516. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. *J Urol* 2007; 177:932-6.
517. Brown EE, Lan Q, Zheng T, Zhang Y, Wang SS, Hoar-Zahm S, Chanock SJ, Rothman N, Baris D. Common variants in genes that mediate immunity and risk of multiple myeloma. *Int J Cancer* 2007; 120(12):2715-22.
518. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2005*. 2007; 1-13.
519. Connecticut Tumor Registry. *Incidence of Pediatric Cancers in Connecticut Towns, 2000-2005*. 2007; 1-25.
520. Gregorio DI, Huang L, DeChello LM, Kulldorff M. Place of residence effect on likelihood of surviving prostate cancer. *Ann Epidemiol* 2007; 17:520-4.
521. Hosgood HD 3rd, Baris D, Zahm SH, Zheng T, Cross AJ. Diet and risk of multiple myeloma in Connecticut women. *Cancer Causes Control* 2007; 18:1065-76.
522. Huang A, Kulldorff M, Gregorio D. A spatial scan statistic for survival data. *Biometrics* 2007; 63:109-18.
523. Koutros S, Holford TR, Hahn T, Lantos PM, McCarthy PL Jr, Risch HA, Swede H. Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. *Leuk Lymphoma* 2007; 48:357-66.
524. Lan Q, Zheng T, Chanock S, Zhang Y, Shen M, Wang SS, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Hosgood D, Boyle P, Rothman N. Genetic variants in caspase genes and susceptibility to non-hodgkin lymphoma. *Carcinogenesis* 2007; 28:823-7.
525. Lan Q, Zheng T, Shen M, Zhang Y, Wang SS, Zahm SH, Holford TR, Leaderer B, Boyle P, Chanock S. Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. *Hum Genet* 2007; 121:161-8.
526. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. *Cancer* 2007; 109:1536-42.
527. Ma X, Selvin S, Raza A, Foti K, Mayne ST. Clustering in the incidence of myelodysplastic syndromes. *Leuk Res* 2007; 31:1683-6.

528. Patel AV, McCullough ML, Pavluck AL, Jacobs EJ, Thun MJ, Calle EE. Glycemic load, glycemic index, and carbohydrate intake in relation to pancreatic cancer risk in a large US cohort. *Cancer Causes Control* 2007; 18:287-94.
529. Polednak AP. Documentation of alcohol use in hospital records of newly diagnosed cancer patients: a population-based study. *Am J Drug Alcohol Abuse* 2007; 33:403-9.
530. Polednak AP. Identifying newly diagnosed Hispanic cancer patients who use a physician with a Spanish-language practice, for studies of quality of cancer treatment. *Cancer Detect Prev* 2007; 31:185-90.
531. Polednak AP. Incidence of skin melanoma in Connecticut towns and counties, 1997-2003. *Conn Med* 2007; 71:275-9.
532. Polednak AP. Prevalence and predictors of comorbid diabetes among newly diagnosed Hispanic cancer patients in Connecticut. *Cancer Detect Prev* 2007; 31:453-6.
533. Polednak AP. Secular trend in U.S. black-white disparities in selected alcohol-related cancer incidence rates. *Alcohol Alcohol* 2007; 42:125-30.
534. Polednak AP. Suicide among breast cancer patients who have had reconstructive surgery: a population-based study. *Psychosomatics* 2007; 48:178-9.
535. Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, Stafford J, Baker F. The Rationale, Design, and Implementation of the American Cancer Society's Studies of Cancer Survivors. *Cancer* 2007; 109:1-12.
536. Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. *Genet Med* 2007; 9:141-9.
537. Terry MB, Gammon MD, Zhang FF, Vaughan TL, Chow WH, Risch HA, Schoenberg JB, Mayne ST, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr, Santella RM. Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas. *Cancer Causes Control* 2007; 18:1039-46.
538. Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L, Boffetta P, Cerhan JR, Maynadie M, Spinelli JJ, Chiu BC, Cocco PL, Mensah F, Zhang Y, Nieters A, Dal Maso L, Bracci PM, Costantini AS, Vineis P, Severson RK, Roman E, Cozen W, Weisenburger D, Davis S, Franceschi S, La Vecchia C, Foretova L, Becker N, Staines A, Vornanen M, Zheng T, Hartge P. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). *Blood* 2007; 109:3479-88.
539. Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. *Cancer Detect Prev* 2007; 31:233-6.
540. Zhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP Sr, Qin Q, Kilfoy B, Han J, Zheng T. Ultraviolet radiation exposure and risk of non-Hodgkin's lymphoma. *Am J Epidemiol* 2007; 165:1255-64.

541. Zhang Y, Wang R, Holford TR, Leaderer B, Zahm SH, Boyle P, Zhu Y, Qin Q, Zheng T. Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. *Cancer Causes Control* 2007; 18:351-9.
542. Baili P, Micheli A, De Angelis R, Weir HK, Francisci S, Santaquilani M, Hakulinen T, Quaresmas M, Coleman MP; CONCORD Working Group. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori* 2008; 94:658-68.
543. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Detecting trends in noisy data series: application to biomarker series. *Am J Epidemiol* 2008; 167:1130-9.
544. Bellera CA, Hanley JA, Joseph L, Albertsen PC. Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. *Ann Epidemiol* 2008; 18:270-82.
545. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, E Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL; CONCORD Working Group. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol* 2008; 9:730-56.
546. Connecticut Tumor Registry. *Cancer Incidence in Connecticut, 2006*. 2008; 1-17.
547. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng T, Zhang Y, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadié M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. *Clin Gastroenterol Hepatol* 2008; 6:451-8.
548. Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjosé S, Chiu BC, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. *Blood* 2008; 111:4029-38.
549. Hosgood HD 3rd, Baris D, Zhang Y, Zhu Y, Zheng T, Yeager M, Welch R, Zahm S, Chanock S, Rothman N, Lan Q. Caspase polymorphisms and genetic susceptibility to multiple myeloma. *Hematol Oncol* 2008; 26:148-51.
550. Irwin ML, Cadmus L, Alvarez-Reeves M, O'Neil M, Mierzejewski E, Latka R, Yu H, Dipietro L, Jones B, Knobf MT, Chung GG, Mayne ST. Recruiting and retaining breast cancer survivors into a randomized controlled exercise trial: the Yale Exercise and Survivorship Study. *Cancer* 2008;112:2593-2606.
551. Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vilà H, Curnen MG, Dubrow R. Explaining the race difference in prostate cancer stage at diagnosis. *Cancer Epidemiol Biomarkers Prev* 2008; 17:2825-34.
552. Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. *J Clin Oncol* 2008;26:392-8.

553. Koutros S, Zhang Y, Zhu Y, Mayne ST, Zahm SH, Holford TR, Leaderer BP, Boyle P, Zheng T. Nutrients contributing to one-carbon metabolism and risk of non-Hodgkin lymphoma subtypes. *Am J Epidemiol* 2008; 167:287-94.
554. Kricker A, Armstrong BK, Hughes AM, Goumas C, Smedby KE, Zheng T, Spinelli JJ, De Sanjosé S, Hartge P, Melbye M, Willett EV, Becker N, Chiu BC, Cerhan JR, Maynadié M, Staines A, Cocco P, Boffeta P; Interlymph Consortium. Personal sun exposure and risk of non-Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. *Int J Cancer* 2008; 122:144-54.
555. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. *J Gen Intern Med* 2008; 23:1809-14.
556. Navarro Silvera SA, Mayne ST, Risch H, Gammon MD, Vaughan TL, Chow WH, Dubrow R, Schoenberg JB, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr. Food group intake and risk of subtypes of esophageal and gastric cancer. *Int J Cancer* 2008; 123:852-60.
557. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. *J Urol* 2008; 179:S40-4.
558. Polednak AP. Estimating the number of U.S. incident cancers attributable to obesity and the impact on temporal trends in incidence rates for obesity-related cancers. *Cancer Detect Prev* 2008; 32:190-9.
559. Polednak AP. Indicators of nutritional screening in hospital records of newly diagnosed Hispanic and Asian-American adult cancer patients in Connecticut. *Nutrition* 2008; 24:1053-6.
560. Polednak AP. Temporal trend in the U.S. black-white disparity in mortality rates from selected alcohol-related chronic diseases. *J Ethn Subst Abuse* 2008; 7:154-64.
561. Polednak AP. Tobacco control indicators and lung cancer rates in young adults by state in the United States. *Tob Control* 2008; 17:66-9.
562. Zhang Y, Sanjose SD, Bracci PM, Morton LM, Wang R, Brennan P, Hartge P, Boffetta P, Becker N, Maynadié M, Foretova L, Cocco P, Staines A, Holford T, Holly EA, Nieters A, Benavente Y, Bernstein L, Zahm SH, Zheng T. Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma. *Am J Epidemiol* 2008; 167:1321-31.
563. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox JW Jr, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. *Nature Genetics* 2009; 41(9):986-990.

564. Bellera CA, Hanley JA, Joseph L, Albertsen PC. A Statistical Evaluation of Rules for Biochemical Failure After Radiotherapy in Men Treated for Prostate Cancer. *Int J Radiat Oncol Biol Phys* 2009; 75:1357-63.
565. Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, Ambinder RF, Zheng T, Mueller NE. Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev* 2009; 18:976-86.
566. Connecticut Tumor Registry. *Cancer in Connecticut 2005 With Focus on Tobacco-Related Cancers*. 2009; 1-35.
567. Ferrucci LM, McCorkle R, Smith T, Stein KD, Cartmel B. Factors related to the use of dietary supplements by cancer survivors. *J Altern Complement Med* 2009; 15:673-80.
568. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. *Cancer Causes Control* 2009; 20:361-8.
569. Han X, Zheng T, Lan Q, Zhang Y, Kilfoy BA, Qin Q, Rothman N, Zahm SH, Holford TR, Leaderer B, Zhang Y. Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev* 2009; 18:1429-38.
570. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. *Cancer Res* 2009; 69:3605-13.
571. Hosgood HD 3rd, Baris D, Zhang Y, Berndt SI, Menashe I, Morton LM, Lee KM, Yeager M, Zahm SH, Chanock S, Zheng T, Lan Q. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. *Leuk Res* 2009; 33:1609-14.
572. Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingeat B, Mayne S, Fraumeni J Jr, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. *Int J Cancer* 2009; 125:2673-8.
573. Hughes KJ, Mayne ST, Blumberg JB, Ribaya-Mercado JD, Johnson EJ, Cartmel B. Plasma Carotenoids and Biomarkers of Oxidative Stress in Patients with prior Head and Neck Cancer. *Biomark Insights* 2009; 4:17-26.
574. Kilfoy BA, Zheng T, Lan Q, Han X, Qin Q, Rothman N, Holford T, Zhang Y. Genetic polymorphisms in glutathione S-transferases and cytochrome P450s, tobacco smoking, and risk of non-Hodgkin lymphoma. *Am J Hematol* 2009; 84:279-82.
575. Koutros S, Baris D, Bell E, Zheng T, Zhang Y, Holford TR, Leaderer BP, Landgren O, Zahm SH. Use of hair colouring products and risk of multiple myeloma among US women. *Occup Environ Med* 2009; 66:68-70.
576. Lan Q, Morton LM, Armstrong B, Hartge P, Menashe I, Zheng T, Purdue MP, Cerhan JR, Zhang Y, Grulich A, Cozen W, Yeager M, Holford TR, Vajdic CM, Davis S, Leaderer B, Kricker A, Schenk M, Zahm SH, Chatterjee N, Chanock SJ, Rothman N, Wang SS. Genetic variation in caspase genes and risk of non-

Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. *Blood* 2009; 114:264-7.

577. Mayne ST, Cartmel B, Kirsh V, Goodwin WJ Jr. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. *Cancer Epidemiol Biomarkers Prev* 2009; 18:3368-74.
578. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE. Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. *Breast Cancer Res* 2009; 11:R64.
579. Morton LM, Purdue MP, Zheng T, Wang SS, Armstrong B, Zhang Y, Menashe I, Chatterjee N, Davis S, Lan Q, Vajdic CM, Severson RK, Holford TR, Kricker A, Cerhan JR, Leaderer B, Grulich A, Yeager M, Cozen W, Hoar Zahm S, Chanock SJ, Rothman N, Hartge P. Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. *Cancer Epidemiol Biomarkers Prev* 2009; 18:1259-70.
580. Palmer JR, Boggs DA, Adams-Campbell LL, Rosenberg L. Family history of cancer and risk of breast cancer in the Black Women's Health Study. *Cancer Causes Control* 2009; 20:1733-7.
581. Pensa M, Swede H, Brockmeyer JA, Gregorio DI. Patterns of HER2 testing in the management of primary breast cancer. *Cancer Epidemiol* 2009; 33:113-7.
582. Polednak AP. Comorbid Mental Disorders in Hospital Records of Hispanic Patients Diagnosed with Cancer in Connecticut. *J Registry Manag* 2009; 36:111-6.
583. Polednak AP. Lung cancer incidence trends by histologic type in areas of California vs. other areas in the Surveillance, Epidemiology and End Results Program. *Cancer Epidemiol* 2009; 33:319-24.
584. Polednak AP. Obtaining Information on language preference among newly diagnosed Hispanic and Asian American cancer patients in Connecticut. *J Registry Manag* 2009; 36:77-82.
585. Polednak AP. Recognition of comorbid diabetes and obesity in hospital records of newly diagnosed cancer patients. *Ann Oncol* 2009; 20:591-2.
586. Polednak AP. Trends in death rates from tobacco-related cardiovascular diseases in selected US states differing in tobacco-control efforts. *Epidemiology* 2009; 20:542-6.
587. Polednak AP. Trends in incidence rates of tobacco-related cancer, selected areas, SEER Program, United States, 1992-2004. *Prev Chronic Dis* 2009; 6:A16.
588. Polednak AP. Vocal fold palsy after surgery in elderly thyroid cancer patients with versus without comorbid diabetes. *Surgery* 2009; 145:685-6.
589. Purdue MP, Lan Q, Wang SS, Kricker A, Menashe I, Zheng TZ, Hartge P, Grulich AE, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Leaderer BP, Cerhan JR, Yeager M, Cozen W, Jacobs K, Davis S, Rothman N, Chanock SJ, Chatterjee N, Armstrong BK. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. *Carcinogenesis* 2009; 30:275-81.

590. Wang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Zahm SH, Boyle P, Dosemeci M, Rothman N, Zhu Y, Qin Q, Zheng T. Occupational exposure to solvents and risk of non-Hodgkin lymphoma in Connecticut women. *Am J Epidemiol* 2009; 169:176-85.
591. Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, Lan Q, Hartge P, Krickler A, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Grulich A, Leaderer BP, Davis S, Cozen W, Yeager M, Chanock SJ, Chatterjee N, Rothman N. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF- κ B transcription factors and non-Hodgkin lymphoma risk. *PLoS One*. 2009; 4:e5360.
592. Zhao L, Portier K, Stein K, Baker F, Smith T. Exploratory factor analysis of the Cancer Problems in Living Scale: a report from the American Cancer Society's Studies of Cancer Survivors. *J Pain Symptom Manag* 2009; 37:676-86.
593. Boggs DA, Palmer JR, Stampfer MJ, Spiegelman D, Adams-Campbell LL, Rosenberg L. Tea and coffee intake in relation to risk of breast cancer in the Black Women's Health Study. *Cancer Causes Control* 2010; 21:1941-8.
594. Boggs DA, Palmer JR, Wise LA, Spiegelman D, Stampfer MJ, Adams-Campbell LL, Rosenberg L. Fruit and vegetable intake in relation to risk of breast cancer in the Black Women's Health Study. *Am J Epidemiol* 2010; 172:1268-79.
595. Buchanich JM, Youk AO, Marsh GM, Kennedy KJ, Esmen NA, Lacey SE, Hancock R, Cunningham MA, Lieberman FS, Fleissner ML. Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. *Ann Epidemiol* 2010; 20:759-65.
596. Han X, Li Y, Huang J, Zhang Y, Holford T, Lan Q, Rothman N, Zheng T, Kosorok MR, Ma S. Identification of predictive pathways for non-hodgkin lymphoma prognosis. *Cancer Inform* 2010; 9:281-92.
597. Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. *Leuk Lymphoma* 2010; 51:1047-54.
598. Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. *Am J Hematol* 2010; 85:51-6.
599. Lee KM, Baris D, Zhang Y, Hosgood HD 3rd, Menashe I, Yeager M, Zahm SH, Wang SS, Purdue MP, Chanock S, Zheng T, Rothman N, Lan Q. Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. *Am J Hematol* 2010; 85:560-3.
600. Li Q, Zheng T, Holford TR, Boyle P, Zhang Y, Dai M. Light at night and breast cancer risk: results from a population-based case-control study in Connecticut, USA. *Cancer Causes Control* 2010; 21:2281-5.
601. Marsh GM, Buchanich JM, Youk AO, Cunningham MA, Lieberman FS, Kennedy KJ, Lacey SE, Hancock RP, Esmen NA, Fleissner ML. Long-term health experience of jet engine manufacturing workers: III. Incidence of malignant central nervous system neoplasms. *Neuroepidemiology* 2010; 35:123-41.
602. McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous primary melanoma and lymphoma. *Ann Plast Surg* 2010; 64:229-32.

603. Polednak AP, Phillips CE. Obtaining data on comorbid diabetes among patients in a U.S. population-based tumor registry. *J Registry Manag* 2010; 37:57-64.
604. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. *Cancer Epidemiol Biomarkers Prev* 2010; 19:2073-9.
605. Ruiz-Narvaez EA, Rosenberg L, Rotimi CN, Cupples LA, Boggs DA, Adeyemo A, Cozier YC, Adams-Campbell LL, Palmer JR. Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women's Health Study. *Breast Cancer Res Treat* 2010; 123:525-30.
606. Ruiz-Narvaez EA, Rosenberg L, Cozier YC, Cupples LA, Adams-Campbell LL, Palmer JR. Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-American women. *Cancer Epidemiol Biomarkers Prev* 2010; 19:1320-7.
607. Shebl FM, Bhatia K, Engels EA. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. *Int J Cancer* 2010; 126:2503-8.
608. Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA. Reduced risk of prostate cancer in U.S. Men with AIDS. *Cancer Epidemiol Biomarkers Prev* 2010; 19:2910-5.
609. Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. *Ann Intern Med* 2010; 153:452-60.
610. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. *J Oncol* 2010; 2010:595167.
611. Wideroff L, Garceau AO, Greene MH, Dunn M, McNeel T, Mai P, Willis G, Gonsalves L, Martin M, Graubard BI. Coherence and completeness of population-based family cancer reports. *Cancer Epidemiol Biomarkers Prev* 2010; 19:799-810.
612. Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. *Cancer Epidemiol Biomarkers Prev* 2011; 20:183-6.
613. Arem H, Irwin ML, Zhou Y, Lu L, Risch H, Yu H. Physical activity and endometrial cancer in a population-based case-control study. *Cancer Causes Control* 2011; 22:219-26.
614. Autier P, Boniol M, Middleton R, Dore JF, Hery C, Zheng T, Gavin A. Advanced breast cancer incidence following population-based mammographic screening. *Ann Oncol* 2011; 22:1726-35.
615. Barry KH, Zhang Y, Lan Q, Zahm SH, Holford TR, Leaderer B, Boyle P, Hosgood HD 3rd, Chanock S, Yeager M, Rothman N, Zheng T. Genetic variation in metabolic genes, occupational solvent exposure, and risk of non-hodgkin lymphoma. *Am J Epidemiol* 2011; 173:404-13.
616. Bertuccio P, La VC, Silverman DT, Petersen GM, Bracci PM, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham ET, Bamlet WR, Holly EA, Lucenteforte E, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Bosetti C, Boffetta P. Cigar and pipe smoking, smokeless tobacco use and

pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol* 2011; 22:1420-6.

617. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. *Cancer Causes Control* 2011;22:1553-1561.
618. Brown SC, Alberts R, Schoenberg M. Cancer incidence and mortality among workers exposed to benzidine. *Am J Ind Med* 2011; 54:300-6.
619. Buchanich JM, Youk AO, Marsh GM, Kennedy KJ, Lacey SE, Hancock RP, Esmen NA, Cunningham MA, Leiberman FS, Fleissner ML. Long-term health experience of jet engine manufacturing workers: V. Issues with the analysis of non-malignant central nervous system neoplasms. *J Registry Manag* 2011; 38:115-9.
620. Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. *Blood* 2011; 117:585-90.
621. Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Family and personal medical history and risk of meningioma. *J Neurosurg* 2011; 115:1072-7.
622. DeLancey JO, Hannan LM, Gapstur SM, Thun MJ. Cigarette smoking and the risk of incident and fatal melanoma in a large prospective cohort study. *Cancer Causes Control* 2011; 22:937-42.
623. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. *JAMA* 2011; 306:1891-901.
624. Ferrucci LM, Cartmel B, Turkman YE, Murphy ME, Smith T, Stein KD, McCorkle R. Causal attribution among cancer survivors of the 10 most common cancers. *J Psychosoc Oncol* 2011; 29:121-40.
625. Hao Y, Landrine H, Smith T, Kaw C, Corral I, Stein K. Residential segregation and disparities in health-related quality of life among Black and White cancer survivors. *Health Psychol* 2011; 30:137-44.
626. Jacobs EJ, Newton CC, Stevens VL, Gapstur SM. A large cohort study of long-term acetaminophen use and prostate cancer incidence. *Cancer Epidemiol Biomarkers Prev* 2011; 20:1322-8.
627. Kasperzyk JL, Chang ET, Birmann BM, Kraft P, Zheng T, Mueller NE. Nutrients and genetic variation involved in one-carbon metabolism and Hodgkin lymphoma risk: a population-based case-control study. *Am J Epidemiol* 2011; 174:816-27.
628. Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, Zhu Y. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. *Int J Mol Epidemiol Genet* 2011; 2:9-18.
629. Lo AM, Tsai WY, Lo KM. The impact of chlordane and dieldrin contamination of well water on cancer rates in North Stamford, Connecticut. *Conn Med* 2011; 75:517-21.

630. Lu L, Risch H, Irwin ML, Mayne ST, Cartmel B, Schwartz P, Rutherford T, Yu H. Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. *Int J Cancer* 2011; 129:1237-43.
631. Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, Gail MH, Greene MH, Willis GB, Wideroff L. Confirmation of family cancer history reported in a population-based survey. *J Natl Cancer Inst* 2011; 103:788-97.
632. Moran MS, Gonsalves L, Goss DM, Ma S. Breast cancers in U.S. residing Indian-Pakistani versus non-Hispanic White women: comparative analysis of clinical-pathologic features, treatment, and survival. *Breast Cancer Res Treat* 2011; 128:543-51.
633. Navarro Silvera SA, Mayne ST, Risch HA, Gammon MD, Vaughan T, Chow WH, Dubin JA, Dubrow R, Schoenberg J, Stanford JL, West AB, Rotterdam H, Blot WJ. Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. *Ann Epidemiol* 2011; 21:543-50.
634. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. *Cancer Epidemiol Biomarkers Prev* 2011;20:1883-1891.
635. Polednak AP. US death rates from myeloproliferative neoplasms, and implications for cancer surveillance. *J Registry Manag* 2011; 38:87-92.
636. Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, Hosgood HD 3rd, Zahm SH, Chanock SJ, Rothman N, Baris D. Variation in innate immunity genes and risk of multiple myeloma. *Hematol Oncol* 2011; 29:42-6.
637. Shen M, Zheng T, Lan Q, Zhang Y, Hosgood HD 3rd, Zahm SH, Holford TR, Leaderer B, Yeager M, Yuenger J, Chanock S, Rothman N. Polymorphisms in integrin genes and lymphoma risk. *Leuk Res* 2011; 35:968-70.
638. Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS. Symptom burden in cancer survivors 1 year after diagnosis: A Report From the American Cancer Society's Studies of Cancer Survivors. *Cancer* 2011; 117:2779-90.
639. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ, Engels EA. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 2011; 103:753-62.
640. Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, Hartge P, Engels EA. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. *JAMA* 2011; 305:1450-9.
641. Soler-Vilá H, Dubrow R, Franco VI, Kasl SV, Jones BA. The prognostic role of cancer-specific beliefs among prostate cancer survivors. *Cancer Causes Control* 2011; 22:251-60.
642. Stevens VL, McCullough ML, Sun J, Jacobs EJ, Campbell PT, Gapstur SM. High levels of folate from supplements and fortification are not associated with increased risk of colorectal cancer. *Gastroenterology* 2011; 141:98-105.

643. Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL, Pensa MA, Gonsalves L, Stevens RG, Runowicz CD. Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study. *Clin Breast Cancer* 2011; 11:332-41.
644. Thong MS, Poll-Franse L, Hoffman RM, Albertsen PC, Hamilton AS, Stanford JL, Penson DF. Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. *BJU Int* 2011; 107:1223-31.
645. Wiemels JL, Wrensch M, Sison JD, Zhou M, Bondy M, Calvocoressi L, Black PM, Yu H, Schildkraut JM, Claus EB. Reduced allergy and immunoglobulin E among adults with intracranial meningioma compared to controls. *Int J Cancer* 2011; 129:1932-9.
646. Wise LA, Palmer JR, Boggs DA, Adams-Campbell LL, Rosenberg L. Abuse victimization and risk of breast cancer in the Black Women's Health Study: abuse and breast cancer risk in black women. *Cancer Causes Control* 2011; 22:659-69.
647. Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch HA. Genetic Effects and Modifiers of Radiotherapy and Chemotherapy on Survival in Pancreatic Cancer. *Pancreas* 2011; 40:657-63.
648. Zhou Y, Irwin ML, Risch HA. Pre- and post-diagnosis body mass index, weight change, and ovarian cancer mortality. *Gynecol Oncol* 2011; 120:209-13.
649. Zhu G, Pan D, Zheng T, Lan Q, Chen X, Chen Y, Kim C, Bi X, Holford T, Boyle P, Leaderer B, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in Th1/Th2 cytokine genes, hormone replacement therapy, and risk of non-Hodgkin lymphoma. *Front Oncol* 2011; 1:00021.
650. Aschebrook-Kilfoy B, Ward MH, Zheng T, Holford TR, Boyle P, Leaderer B, Zhang Y. Dietary nitrate and nitrite intake and non-Hodgkin lymphoma survival. *Nutr Cancer* 2012; 64:488-92.
651. Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. *J Cancer Surviv* 2012; 6:102-14.
652. Bassig BA, Zheng T, Zhang Y, Berndt SI, Holford TR, Hosgood HD 3rd, Hu W, Leaderer B, Yeager M, Menashe I, Boyle P, Xu J, Zou K, Zhu Y, Chanock S, Rothman N, Lan Q. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. *Environ Mol Mutagen* 2012; 53:145-51.
653. Becker N, Falster MO, Vajdic CM, de SS, Martinez-Maza O, Bracci PM, Melbye M, Smedby KE, Engels EA, Turner J, Vineis P, Costantini AS, Holly EA, Spinelli JJ, La VC, Zheng T, Chiu BC, Montella M, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Cozen W, Grulich AE, Newton R. Self-reported history of infections and the risk of non-Hodgkin lymphoma: An InterLymph pooled analysis. *Int J Cancer* 2012; 131:2342-8.
654. Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. *Am J Hematol* 2012; 87:766-9.
655. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Cardiometabolic factors and breast cancer risk in U.S. black women. *Breast Cancer Res Treat* 2012; 134:1247-56.

656. Brenner BM, Swede H, Jones BA, Anderson GR, Stoler DL. Genomic instability measured by inter- (simple sequence repeat) PCR and high-resolution microsatellite instability are prognostic of colorectal carcinoma survival after surgical resection. *Ann Surg Oncol* 2012; 19:344-50.
657. Calvo-coressi L, Stowe MH, Carter D, Claus EB. Postmenopausal hormone therapy and ductal carcinoma in situ: a population-based case-control study. *Cancer Epidemiol* 2012; 36:161-8.
658. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. *J Clin Oncol* 2012; 30:42-52.
659. Claus EB, Walsh KM, Calvo-coressi L, Bondy ML, Schildkraut JM, Wrensch M, Wiemels JL. Cigarette smoking and risk of meningioma: the effect of gender. *Cancer Epidemiol Biomarkers Prev* 2012; 21:943-50.
660. Claus EB, Calvo-coressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Dental x-rays and risk of meningioma. *Cancer* 2012; 118:4530-7.
661. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. *J Clin Oncol* 2012; 30:53-9.
662. Diver WR, Patel AV, Thun MJ, Teras LR, Gapstur SM. The association between cigarette smoking and non-Hodgkin lymphoid neoplasms in a large US cohort study. *Cancer Causes Control* 2012; 23:1231-40.
663. Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, Fontham EH, Maisonneuve P, Bueno-de-Mesquita HB, Ghadirian P, Kurtz RC, Ludwig E, Yu H, Lowenfels AB, Seminara D, Petersen GM, La VC, Boffetta P. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol* 2012; 23:2964-70.
664. Francis JH, Kleinerman RA, Seddon JM, Abramson DH. Increased risk of secondary uterine leiomyosarcoma in hereditary retinoblastoma. *Gynecol Oncol* 2012; 124:254-9.
665. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. *Mol Carcinog* 2012; 51:923-9.
666. Gapstur SM, Diver WR, McCullough ML, Teras LR, Thun MJ, Patel AV. Alcohol Intake and the Incidence of Non-Hodgkin Lymphoid Neoplasms in the Cancer Prevention Study II Nutrition Cohort. *Am J Epidemiol* 2012; 176:60-9.
667. Gong J, Hutter C, Baron JA, Berndt S, Caan B, Campbell PT, Casey G, Chan AT, Cotterchio M, Fuchs CS, Gallinger S, Giovannucci E, Harrison T, Hayes R, Hsu L, Jiao S, Lin Y, Lindor NM, Newcomb P, Pflugeisen B, Phipps AI, Rohan T, Schoen R, Seminara D, Slattery ML, Stelling D, Thomas F, Warnick G, White E, Potter J, Peters U. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. *Cancer Epidemiol Biomarkers Prev* 2012; 21:1974-85.
668. Gonsalves L, Cartmel B, Mueller L. The Burden of Cancer in Connecticut. *Conn Med* 2012; 76:335-51.

669. Jacobs EJ, Stevens VL, Newton CC, Gapstur SM. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Causes Control* 2012; 23:1289-96.
670. Jiao J, Zheng T, Lan Q, Chen Y, Deng Q, Bi X, Kim C, Holford T, Leaderer B, Boyle P, Ba Y, Xia Z, Chanock SJ, Rothman N, Zhang Y. Occupational solvent exposure, genetic variation of DNA repair genes, and the risk of non-Hodgkin's lymphoma. *Eur J Cancer Prev* 2012; 21:580-4.
671. Kane EV, Roman E, Becker N, Bernstein L, Boffetta P, Bracci PM, Cerhan JR, Chiu BC, Cocco P, Costas L, Foretova L, Holly EA, La VC, Matsuo K, Maynadie M, Sanjose S, Spinelli JJ, Staines A, Talamini R, Wang SS, Zhang Y, Zheng T, Kricker A. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. *Ann Oncol* 2012; 23:2362-74.
672. Kim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Genetic polymorphisms in oxidative stress pathway genes and modification of BMI and risk of non-Hodgkin lymphoma. *Cancer Epidemiol Biomarkers Prev* 2012; 21:866-8.
673. Li D, Duell EJ, Yu K, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, Dong X, Wheeler B, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Hartge P, Hoover RN, Holly EA, Jacobs EJ, Klein AP, Lacroix A, Mandelson MT, Petersen G, Zheng W, Agalliu I, Albanes D, Boutron-Ruault MC, Bracci PM, Buring JE, Canzian F, Chang K, Chanock SJ, Cotterchio M, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hoffman Bolton JA, Hunter DJ, Hutchinson A, Jacobs KB, Jenab M, Khaw KT, Kraft P, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Patel AV, Rabe KG, Riboli E, Shu XO, Tjonneland A, Tobias GS, Trichopoulos D, Virtamo J, Visvanathan K, Watters J, Yu H, Zeleniuch-Jacquotte A, Amundadottir L, Stolzenberg-Solomon RZ. Pathway Analysis of Genome-wide Association Study Data Highlights Pancreatic Development Genes as Susceptibility Factors for Pancreatic Cancer. *Carcinogenesis* 2012; 33:1384-90.
674. Li J, Cone JE, Kahn AR, Brackbill RM, Farfel MR, Greene CM, Hadler JL, Stayner LT, Stellman SD. Association between World Trade Center exposure and excess cancer risk. *JAMA* 2012; 308:2479-88.
675. Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, Yu H, Wentzensen N, Lambrechts D, Dork T, Dubrowinskaja N, Goodman MT, Salvesen HB, Fasching PA, Scott RJ, Delahanty R, Zheng Y, O'Mara T, Healey CS, Hodgson S, Risch H, Yang HP, Amant F, Turmanov N, Schwake A, Lurie G, Trovik J, Beckmann MW, Ashton K, Ji BT, Bao PP, Howarth K, Lu L, Lissowska J, Coenegrachts L, Kaidarova D, Durst M, Thompson PJ, Krakstad C, Ekici AB, Otton G, Shi J, Zhang B, Gorman M, Brinton L, Coosemans A, Matsuno RK, Halle MK, Hein A, Proietto A, Cai H, Lu W, Dunning A, Easton D, Gao YT, Cai Q, Spurdle AB, Shu XO. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. *Cancer Epidemiol Biomarkers Prev* 2012; 21:980-7.
676. McCullough ML, Jacobs EJ, Shah R, Campbell PT, Gapstur SM. Garlic consumption and colorectal cancer risk in the CPS-II Nutrition Cohort. *Cancer Causes Control* 2012; 23:1643-51.
677. Nieters A, Conde L, Slager SL, Brooks-Wilson A, Morton L, Skibola DR, Novak AJ, Riby J, Ansell SM, Halperin E, Shanafelt TD, Agana L, Wang AH, De Roos AJ, Severson RK, Cozen W, Spinelli J, Butterbach K, Becker N, de SS, Benavente Y, Cocco P, Staines A, Maynadie M, Foretova L, Boffetta P, Brennan P, Lan Q, Zhang Y, Zheng T, Purdue M, Armstrong B, Kricker A, Vajdic CM, Grulich A, Smith MT, Bracci PM, Chanock SJ, Hartge P, Cerhan JR, Wang SS, Rothman N, Skibola CF. PRRC2A and BCL2L11 gene variants

influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. *Blood* 2012; 120:4645-8.

678. Palmer JR, Boggs DA, Wise LA, Adams-Campbell LL, Rosenberg L. Individual and neighborhood socioeconomic status in relation to breast cancer incidence in African-American women. *Am J Epidemiol* 2012; 176:1141-6.
679. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 2012; 13:385-94.
680. Persson EC, Shiels MS, Dawsey SM, Bhatia K, Anderson LA, Engels EA. Increased Risk of Stomach and Esophageal Malignancies in People with AIDS. *Gastroenterology* 2012; 143:943-50.
681. Polednak AP. Recent decline in the U.S. death rate from myeloproliferative neoplasms, 1999-2006. *Cancer Epidemiol* 2012; 36:133-6.
682. Polednak AP, Phillips C. Coding of specific subgroups of myelodysplastic syndromes in a population-based cancer registry: prospects for improvement. *J Registry Manag* 2012; 39:107-14.
683. Polednak AP, Phillips C. Leukemia as a Cause of Death among Patients with Myelodysplastic Syndromes (MDS) in a Population- Based Cancer Registry: Improving Estimates of MDS-Related Mortality in the Population. *J Registry Manag* 2012; 39:115-20.
684. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. *Cancer* 2012; 118:6226-33.
685. Shebl FM, Engels EA, Goedert JJ. Opportunistic Intestinal Infections and Risk of Colorectal Cancer Among People with AIDS. *AIDS Res Hum Retroviruses* 2012; 28:994-9.
686. Shiels MS, Pfeiffer RM, Chaturvedi AK, Kreimer AR, Engels EA. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. *J Natl Cancer Inst* 2012; 104:1591-8.
687. Shiels MS, Engels EA. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: Clues for possible immunosuppression-related or infectious etiology. *Cancer* 2012; 118:4869-76.
688. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods. *AIDS* 2012; 26:1311-8.
689. Simard EP, Shiels MS, Bhatia K, Engels EA. Long-term cancer risk among people diagnosed with AIDS during childhood. *Cancer Epidemiol Biomarkers Prev* 2012; 21:148-54.
690. Stevens VL, Jacobs EJ, Sun J, McCullough ML, Patel AV, Gaudet MM, Teras LR, Gapstur SM. Weight cycling and risk of endometrial cancer. *Cancer Epidemiol Biomarkers Prev* 2012; 21:747-52.

691. Teras LR, Gapstur SM, Diver WR, Birmann BM, Patel AV. Recreational physical activity, leisure sitting time and risk of non-Hodgkin lymphoid neoplasms in the American Cancer Society Cancer Prevention Study II Cohort. *Int J Cancer* 2012; 131:1912-20.
692. Yu M, Ferrucci LM, McCorkle R, Ercolano E, Smith T, Stein KD, Cartmel B. Employment experience of cancer survivors 2 years post-diagnosis in the Study of Cancer Survivors-I. *J Cancer Surviv* 2012; 6:210-8.
693. Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H. Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1. *Breast Cancer Res Treat* 2012;133:127-135.
694. Abrams JA, Gonsalves L, Neugut AI. Diverging Trends in the Incidence of Reflux-related and Helicobacter pylori-related Gastric Cardia Cancer. *J Clin Gastroenterol* 2013; 47:322-7.
695. Arem H, Neuhaus ML, Irwin ML, Cartmel B, Lu L, Risch H, Mayne ST, Yu H. Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case-control study. *Eur J Nutr* 2013; 52:1251-60.
696. Backes DM, Siddiq A, Cox DG, Calboli FC, Gaziano JM, Ma J, Stampfer M, Hunter DJ, Camargo CA, Michaud DS. Single-nucleotide polymorphisms of allergy-related genes and risk of adult glioma. *J Neurooncol* 2013;113:229-238.
697. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. *J Natl Cancer Inst* 2013;105:95-103.
698. Bao Y, Giovannucci EL, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso HD, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin L, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts. *Cancer Epidemiol Biomarkers Prev* 2013; 22:855-61.
699. Bao Y, Hu FB, Giovannucci EL, Wolpin BM, Stampfer MJ, Willett WC, Fuchs CS. Nut consumption and risk of pancreatic cancer in women. *Br J Cancer* 2013; 109:2911-6.
700. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, Cozen W, Monnereau A, Wang SS, Kelly RS, Lan Q, Teras LR, Chatterjee N, Chung CC, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Armstrong BK, Cocco P, Zhang Y, Severi G, Zeleniuch-Jacquotte A, Lawrence C, Burdette L, Yuenger J, Hutchinson A, Jacobs KB, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Wang AH, Smedby KE, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Jones B, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Holly EA, Smith MT, Jackson RD, Tinker LF, Benavente Y, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Leis JF, Cunningham JM, Weinberg JB, Morrison VA, Caporaso NE, Norman AD, Linet MS, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RC, Travis RC, Giles GG, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Offit K, Zelenetz A, Klein RJ, Spinelli JJ, Bertrand KA, Laden F, Giovannucci E, Kraft P, Krickler A, Turner J, Vajdic CM, Ennas MG, Ferri GM, Miligi L, Liang L, Sampson J, Crouch S, Park JH, North KE, Cox A, Snowden JA, Wright J, Carracedo A, Lopez-Otin C, Bea S, Salaverria I, Martin-Garcia D, Campo E, Fraumeni JF, Jr., de SS,

- Hjalgrim H, Cerhan JR, Chanock SJ, Rothman N, Slager SL. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nat Genet* 2013; 45:868-76.
701. Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz VS, Visscher D, Norman A, Couch F, Shepherd J, Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM. Mammographic density and risk of breast cancer by age and tumor characteristics. *Breast Cancer Res* 2013; 15:R104.
702. Bertrand KA, Giovannucci E, Zhang SM, Laden F, Rosner B, Birmann BM. A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. *Cancer Prev Res (Phila)* 2013; 6:864-73.
703. Bethea TN, Rosenberg L, Charlot M, O'Connor GT, Adams-Campbell LL, Palmer JR. Obesity in relation to lung cancer incidence in African American women. *Cancer Causes Control* 2013; 24:1695-703.
704. Boggs DA, Rosenberg L, Pencina MJ, Adams-Campbell LL, Palmer JR. Validation of a Breast Cancer Risk Prediction Model Developed for Black Women. *J Natl Cancer Inst* 2013; 105:361-7.
705. Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Trabert B, Niwa S, Moghissi KS. Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort. *Hum Reprod* 2013; 28:2813-21.
706. Chen Q, Zheng T, Lan Q, Lerro C, Zhao N, Qin Q, Hu X, Huang H, Liang J, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Single-Nucleotide Polymorphisms in Genes Encoding for CC Chemokines were Not Associated with the Risk of Non-Hodgkin Lymphoma. *Cancer Epidemiol Biomarkers Prev* 2013; 22:1332-5.
707. Chen Y, Lan Q, Zheng T, Zhao N, Holford TR, Lerro C, Dai M, Huang H, Liang J, Ma S, Leaderer B, Boyle P, Chanock S, Rothman N, Zhang Y. Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma. *Leuk Res* 2013; 37:1120-4.
708. Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma. *Am J Hematol* 2013; 88:606-11.
709. Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martinez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA. Risk of lymphoma subtypes after solid organ transplantation in the United States. *Br J Cancer* 2013; 109:280-8.
710. Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. *J Neurosurg* 2013; 118:649-56.
711. Delahanty RJ, Xiang YB, Spurdle A, Beeghly-Fadiel A, Long J, Thompson D, Tomlinson I, Yu H, Lambrechts D, Dork T, Goodman MT, Zheng Y, Salvesen HB, Bao PP, Amant F, Beckmann MW, Coeneegrachts L, Coosemans A, Dubrowinskaja N, Dunning A, Runnebaum IB, Easton D, Ekici AB, Fasching PA, Halle MK, Hein A, Howarth K, Gorman M, Kaydarova D, Krakstad C, Lose F, Lu L, Lurie G, O'Mara T, Matsuno RK, Pharoah P, Risch H, Corssen M, Trovik J, Turmanov N, Wen W, Lu W, Cai Q, Zheng W, Shu XO. Polymorphisms in inflammation pathway genes and endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev* 2013; 22:216-23.

712. Deng Q, Zheng T, Lan Q, Lan Y, Holford T, Chen Y, Dai M, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y. Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin lymphoma. *Eur J Cancer Prev* 2013; 22:77-82.
713. Engels EA, Clarke CA, Pfeiffer RM, Lynch CF, Weisenburger DD, Gibson TM, Landgren O, Morton LM. Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. *Am J Transplant* 2013; 13:1523-32.
714. Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, Webb PM, Jordan SJ, Rossing MA, Doherty JA, Lurie G, Thompson PJ, Carney ME, Goodman MT, Ness RB, Modugno F, Edwards RP, Bunker CH, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Cramer DW, Terry KL, Vitonis AF, Bandera EV, Olson SH, King M, Chandran U, Kiemeny LA, Massuger LF, van Altena AM, Vermeulen SH, Brinton L, Wentzensen N, Lissowska J, Yang HP, Moysich KB, Odunsi K, Kasza K, Odunsi-Akanji O, Song H, Pharaoh P, Shah M, Whittemore AS, McGuire V, Sieh W, Sutphen R, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Risch HA, Jensen A. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. *Cancer Causes Control* 2013; 24:989-1004.
715. Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II. *Breast Cancer Res* 2013; 15:R19.
716. Fung TT, Chiuve SE, Willett WC, Hankinson SE, Hu FB, Holmes MD. Intake of specific fruits and vegetables in relation to risk of estrogen receptor-negative breast cancer among postmenopausal women. *Breast Cancer Res Treat* 2013; 138:925-30.
717. Gao Y, Li Q, Bassig BA, Chang ET, Dai M, Qin Q, Zhang Y, Zheng T. Subtype of dietary fat in relation to risk of Hodgkin lymphoma: a population-based case-control study in Connecticut and Massachusetts. *Cancer Causes Control* 2013; 24:485-94.
718. Gaudet MM, Patel AV, Sun J, Teras LR, Gapstur SM. Tubal Sterilization and Breast Cancer Incidence: Results From the Cancer Prevention Study II Nutrition Cohort and Meta-Analysis. *Am J Epidemiol* 2013; 177:492-9.
719. Geller AC, Clapp RW, Sober AJ, Gonsalves L, Mueller L, Christiansen CL, Shaikh W, Miller DR. Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. *J Clin Oncol* 2013;31:4172-4178.
720. Genkinger JM, Makambi KH, Palmer JR, Rosenberg L, Adams-Campbell LL. Consumption of dairy and meat in relation to breast cancer risk in the Black Women's Health Study. *Cancer Causes Control* 2013; 24:675-84.
721. Gibson TM, Smedby KE, Skibola CF, Hein DW, Slager SL, de SS, Vajdic CM, Zhang Y, Chiu BC, Wang SS, Hjalgrim H, Nieters A, Bracci PM, Kricker A, Zheng T, Kolar C, Cerhan JR, Darabi H, Becker N, Conde L, Holford TR, Weisenburger DD, De Roos AJ, Butterbach K, Riby J, Cozen W, Benavente Y, Palmers C, Holly EA, Sampson JN, Rothman N, Armstrong BK, Morton LM. Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. *Cancer Causes Control* 2013; 24:125-34.
722. Gregorio DI, Samociuk H. Prostate cancer incidence in light of the spatial distribution of another screening-detectable cancer. *Spat Spatiotemporal Epidemiol* 2013;6:1-6.

723. Hall EC, Engels EA, Montgomery RA, Segev DL. Cancer Risk After ABO-Incompatible Living-Donor Kidney Transplantation. *Transplantation* 2013; 96:476-9.
724. Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation. *Cancer* 2013; 119:2300-8.
725. Hall EC, Segev DL, Engels EA. Racial/Ethnic differences in cancer risk after kidney transplantation. *Am J Transplant* 2013; 13:714-20.
726. Heaphy CM, Yoon GS, Peskoe SB, Joshu CE, Lee TK, Giovannucci E, Mucci LA, Kenfield SA, Stampfer MJ, Hicks JL, De Marzo AM, Platz EA, Meeker AK. Prostate Cancer Cell Telomere Length Variability and Stromal Cell Telomere Length as Prognostic Markers for Metastasis and Death. *Cancer Discov* 2013; 3:1130-41.
727. Hefti MM, Hu R, Knoblauch NW, Collins LC, Haibe-Kains B, Tamimi RM, Beck AH. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. *Breast Cancer Res* 2013; 15:R68.
728. Hoffman AE, Liu R, Fu A, Zheng T, Slack F, Zhu Y. Targetome profiling, pathway analysis and genetic association study implicate miR-202 in lymphomagenesis. *Cancer Epidemiol Biomarkers Prev* 2013; 22:327-36.
729. Holmes MD, Hankinson SE, Feskanich D, Chen WY. Beta blockers and angiotensin-converting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. *Breast Cancer Res Treat* 2013; 139:507-13.
730. Hu W, Bassig BA, Xu J, Zheng T, Zhang Y, Berndt SI, Holford TR, Hosgood HD 3rd, Leaderer B, Yeager M, Menashe I, Boyle P, Zou K, Zhu Y, Chanock S, Lan Q, Rothman N. Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma. *Environ Mol Mutagen* 2013; 54:72-7.
731. Izano MA, Fung TT, Chiuve SS, Hu FB, Holmes MD. Are diet quality scores after breast cancer diagnosis associated with improved breast cancer survival? *Nutr Cancer* 2013; 65:820-6.
732. Joh HK, Giovannucci EL, Bertrand KA, Lim S, Cho E. Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer. *J Natl Cancer Inst* 2013; 105:726-32.
733. Jung S, Wu K, Giovannucci E, Spiegelman D, Willett WC, Smith-Warner SA. Carotenoid intake and risk of colorectal adenomas in a cohort of male health professionals. *Cancer Causes Control* 2013; 24:705-17.
734. Kane EV, Bernstein L, Bracci PM, Cerhan JR, Costas L, Dal ML, Holly EA, La VC, Matsuo K, Sanjose S, Spinelli JJ, Wang SS, Zhang Y, Zheng T, Roman E, Krickler A. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. *Ann Oncol* 2013; 24:433-41.
735. Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2013; 22:2354-63.
736. Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Kobel M, Lurie G, Thompson PJ, Carney ME, Moysich K, Edwards R, Bunker C, Jensen A,

- Hogdall E, Cramer DW, Vitonis AF, Olson SH, King M, Chandran U, Lissowska J, Garcia-Closas M, Yang H, Webb PM, Schildkraut JM, Goodman MT, Risch HA. Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. *BMC Cancer* 2013; 13:28.
737. Kennedy KJ, Esmen NA, Hancock RP, Lacey SE, Marsh GM, Buchanich JM, Youk AO. Long-Term Health Experience of Jet Engine Manufacturing Workers: VII: Occupational Exposures. *J Occup Environ Med* 2013; 55:676-89.
738. Koshiol J, Pawlish K, Goodman MT, McGlynn KA, Engels EA. Risk of Hepatobiliary Cancer After Solid Organ Transplant in the United States. *Clin Gastroenterol Hepatol* 2013; Epub 19 Dec 2013.
739. Lee HJ, Wu K, Cox DG, Hunter D, Hankinson SE, Willett WC, Sinha R, Cho E. Polymorphisms in xenobiotic metabolizing genes, intakes of heterocyclic amines and red meat, and postmenopausal breast cancer. *Nutr Cancer* 2013; 65:1122-31.
740. Li Q, Chang ET, Bassig BA, Dai M, Qin Q, Gao Y, Zhang Y, Zheng T. Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts. *Cancer Causes Control* 2013; 24:287-95.
741. Li Q, Holford TR, Zhang Y, Boyle P, Mayne ST, Dai M, Zheng T. Dietary fiber intake and risk of breast cancer by menopausal and estrogen receptor status. *Eur J Nutr* 2013; 52:217-23.
742. Li X, Liang L, Zhang M, Song F, Nan H, Wang LE, Wei Q, Lee JE, Amos CI, Qureshi AA, Han J. Obesity-related genetic variants, human pigmentation, and risk of melanoma. *Hum Genet* 2013; 132:793-801.
743. Liu JJ, Hazra A, Giovannucci E, Hankinson SE, Rosner B, De V, I. One-carbon metabolism factors and endometrial cancer risk. *Br J Cancer* 2013; 108:183-7.
744. Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, Connolly JL, Chen WY, Willett WC, Tamimi RM. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. *J Natl Cancer Inst* 2013; 105:1571-78.
745. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. *J Natl Cancer Inst* 2013; 105:1151-6.
746. Madeleine MM, Finch JL, Lynch CF, Goodman MT, Engels EA. HPV-related cancers after solid organ transplantation in the United States. *Am J Transplant* 2013; 13:3202-9.
747. Marsh GM, Buchanich JM, Youk AO, Downing S, Esmen NA, Kennedy KJ, Lacey SE, Hancock RP, Fleissner ML, Lieberman FS. Long-Term Health Experience of Jet Engine Manufacturing Workers: Results From a 12-Year Exploratory Investigation. *J Occup Environ Med* 2013; 55:652-3.
748. Marsh GM, Youk AO, Buchanich JM, Downing S, Kennedy KJ, Esmen NA, Hancock RP, Lacey SE, Pierce JS, Fleissner ML. Long-Term Health Experience of Jet Engine Manufacturing Workers: VIII. Glioblastoma Incidence in Relation to Workplace Experiences With Parts and Processes. *J Occup Environ Med* 2013; 55: 690-708.
749. Marsh GM, Youk AO, Buchanich JM, Xu H, Downing S, Kennedy KJ, Esmen NA, Hancock RP, Lacey SE, Fleissner ML. Long-Term Health Experience of Jet Engine Manufacturing Workers: VI: Incidence of

Malignant Central Nervous System Neoplasms in Relation to Estimated Workplace Exposures. *J Occup Environ Med* 2013; 55:654-75.

750. Mbulaiteye SM, Clarke CA, Morton LM, Gibson TM, Pawlish K, Weisenburger DD, Lynch CF, Goodman MT, Engels EA. Burkitt lymphoma risk in U.S. solid organ transplant recipients. *Am J Hematol* 2013; 88:245-50.
751. Meng S, Zhang X, Giovannucci EL, Ma J, Fuchs CS, Cho E. No association between garlic intake and risk of colorectal cancer. *Cancer Epidemiol* 2013; 37:152-5.
752. Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K, Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with beta-catenin (CTNNB1) status. *Cancer Res* 2013; 73:1600-10.
753. Nan H, Giovannucci EL, Wu K, Selhub J, Paul L, Rosner B, Fuchs CS, Cho E. Pre-diagnostic leukocyte genomic DNA methylation and the risk of colorectal cancer in women. *PLoS One* 2013; 8:e59455.
754. Nan H, Lee JE, Rimm EB, Fuchs CS, Giovannucci EL, Cho E. Prospective study of alcohol consumption and the risk of colorectal cancer before and after folic acid fortification in the United States. *Ann Epidemiol* 2013; 23:558-63.
755. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and risk of colorectal cancer according to BRAF mutation status. *JAMA* 2013; 309:2563-71.
756. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013; 369:1095-105.
757. Palmer JR, Ruiz-Narvaez EA, Rotimi CN, Cupples LA, Cozier YC, Adams-Campbell LL, Rosenberg L. Genetic susceptibility loci for subtypes of breast cancer in an African American population. *Cancer Epidemiol Biomarkers Prev* 2013; 22:127-34.
758. Peters U, Jiao S, Schumacher FR, Hutter CM, Aragaki AK, Baron JA, Berndt SI, Bezieau S, Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chan AT, Chang-Claude J, Chanock SJ, Chen LS, Coetzee GA, Coetzee SG, Conti DV, Curtis KR, Duggan D, Edwards T, Fuchs CS, Gallinger S, Giovannucci EL, Gogarten SM, Gruber SB, Haile RW, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Hopper JL, Hudson TJ, Hunter DJ, Jackson RD, Jee SH, Jenkins MA, Jia WH, Kolonel LN, Kooperberg C, Kury S, Lacroix AZ, Laurie CC, Laurie CA, Le ML, Lemire M, Levine D, Lindor NM, Liu Y, Ma J, Makar KW, Matsuo K, Newcomb PA, Potter JD, Prentice RL, Qu C, Rohan T, Rosse SA, Schoen RE, Seminara D, Shrubsole M, Shu XO, Slattery ML, Taverna D, Thibodeau SN, Ulrich CM, White E, Xiang Y, Zanke BW, Zeng YX, Zhang B, Zheng W, Hsu L. Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. *Gastroenterology* 2013; 144:799-807.
759. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despiere E, Doherty JA, Dork

T, du BA, Durst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, Hogdall E, Hogdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeny LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubinski J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permut-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nat Genet* 2013; 45:362-70.

760. Polednak AP. Trend (1999-2009) in U.S. death rates from myelodysplastic syndromes: Utility of multiple causes of death in surveillance. *Cancer Epidemiol* 2013; 37:569-74.
761. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, Rosner B, Webb PM, Cramer DW, Wentzensen N, Terry KL, Tworoger SS. Hormonal and reproductive risk factors for epithelial ovarian cancer by tumor aggressiveness. *Cancer Epidemiol Biomarkers Prev* 2013; 22:429-37.
762. Prescott J, Bertrand KA, Poole EM, Rosner BA, Tworoger SS. Surrogates of long-term vitamin d exposure and ovarian cancer risk in two prospective cohort studies. *Cancers (Basel)* 2013; 5:1577-600.
763. Richman EL, Kenfield SA, Chavarro JE, Stampfer MJ, Giovannucci EL, Willett WC, Chan JM. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. *JAMA Intern Med* 2013; 173:1318-26.
764. Rosenberg L, Boggs DA, Bethea TN, Wise LA, Adams-Campbell LL, Palmer JR. A prospective study of smoking and breast cancer risk among African-American women. *Cancer Causes Control* 2013; 24:2207-15.
765. Ruiz-Narvaez EA, Rosenberg L, Yao S, Rotimi CN, Cupples AL, Bandera EV, Ambrosone CB, Adams-Campbell LL, Palmer JR. Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African-American women. *Carcinogenesis* 2013; 34:287-91.
766. Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. *Clin Cancer Res* 2013; 19:1612-9.
767. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Kobel M, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, van den Berg D, van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K,

Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeny LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Hogdall CK, Hogdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Durst M, du BA, Dork T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A, Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, Lu K, Hildebrandt MA, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, Goode EL, Pearce CL. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun* 2013; 4:1628.

768. Shui IM, Mucci LA, Wilson KM, Kraft P, Penney KL, Stampfer MJ, Giovannucci E. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. *Cancer Epidemiol Biomarkers Prev* 2013; 22:118-26.
769. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ, Goodman MT, Lurie G, Chang-Claude J, Rudolph A, Kjaer SK, Jensen A, Hogdall E, Bandera EV, Olson SH, King MG, Rodriguez-Rodriguez L, Kiemeny LA, Marees T, Massuger LF, van Altena AM, Ness RB, Cramer DW, Pike MC, Pearce CL, Berchuck A, Schildkraut JM, Whittemore AS. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *Int J Epidemiol* 2013; 42:579-89.
770. Solan S, Wallenstein S, Shapiro M, Teitelbaum SL, Stevenson L, Kochman A, Kaplan J, Dellenbaugh C, Kahn A, Biro FN, Crane M, Crowley L, Gabilove J, Gonsalves L, Harrison D, Herbert R, Luft B, Markowitz SB, Moline J, Niu X, Sacks H, Shukla G, Udasin I, Lucchini RG, Boffetta P, Landrigan PJ. Cancer incidence in world trade center rescue and recovery workers, 2001-2008. *Environ Health Perspect* 2013; 121:699-704.
771. Song F, Qureshi AA, Giovannucci EL, Fuchs CS, Chen WY, Stampfer MJ, Han J. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. *PLoS Med* 2013; 10:e1001433.
772. Tantamango-Bartley Y, Jaceldo-Siegl K, Fan J, Fraser G. Vegetarian Diets and the Incidence of Cancer in a Low-risk Population. *Cancer Epidemiol Biomarkers Prev* 2013; 22:286-94.
773. Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. *Fertil Steril* 2013; 100:1660-6.
774. Warner ET, Tamimi RM, Boggs DA, Rosner B, Rosenberg L, Colditz GA, Palmer JR. Estrogen receptor positive tumors: Do reproductive factors explain differences in incidence between black and white women? *Cancer Causes Control* 2013; 24:731-9.
775. Wiemels JL, Bracci PM, Wrensch M, Schildkraut J, Bondy M, Pfefferle J, Zhou M, Sison J, Calvocoressi L, Claus EB. Assessment of autoantibodies to meningioma in a population-based study. *Am J Epidemiol* 2013; 177:75-83.

776. Wu T, Wang Y, Ho SM, Giovannucci E. Plasma levels of nitrate and risk of prostate cancer: a prospective study. *Cancer Epidemiol Biomarkers Prev* 2013; 22:1210-8.
777. Xie J, Terry KL, Poole EM, Wilson KM, Rosner BA, Willett WC, Vesper HW, Tworoger SS. Acrylamide hemoglobin adduct levels and ovarian cancer risk: a nested case-control study. *Cancer Epidemiol Biomarkers Prev* 2013; 22:653-60.
778. Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2013; 22:1142-52.
779. Youk AO, Marsh GM, Buchanich JM, Downing S, Kennedy KJ, Esmen NA, Hancock RP, Lacey SE. Long-Term Health Experience of Jet Engine Manufacturing Workers: IX. Further Investigation of General Mortality Patterns in Relation to Workplace Exposures. *J Occup Environ Med* 2013; 55:709-21.
780. Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. *J Clin Oncol* 2013; 31:4229-34.
781. Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S, Willett WC, Ma J. Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women. *Sleep* 2013; 36:681-8.
782. Zhang M, Song F, Liang L, Nan H, Zhang J, Liu H, Wang LE, Wei Q, Lee JE, Amos CI, Kraft P, Qureshi AA, Han J. Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans. *Hum Mol Genet* 2013; 22:2948-59.
783. Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. *Breast Cancer Res Treat* 2013; 137:883-92.
784. Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. *Cancer Epidemiol Biomarkers Prev* 2013; 22:1984-93.
785. Boggs DA, Palmer JR, Rosenberg L. Bilateral oophorectomy and risk of cancer in African American women. *Cancer Causes Control* 2014; 25:507-13.
786. De V, I, Prescott J, Setiawan VW, Olson SH, Wentzensen N, Attia J, Black A, Brinton L, Chen C, Chen C, Cook LS, Crous-Bou M, Doherty J, Dunning AM, Easton DF, Friedenreich CM, Garcia-Closas M, Gaudet MM, Haiman C, Hankinson SE, Hartge P, Henderson BE, Holliday E, Horn-Ross PL, Hunter DJ, Le ML, Liang X, Lissowska J, Long J, Lu L, Magliocco AM, McEvoy M, O'Mara TA, Orlov I, Painter JN, Pooler L, Rastogi R, Rebbeck TR, Risch H, Sacerdote C, Schumacher F, Scott RJ, Sheng X, Shu XO, Spurdle AB, Thompson D, Vanden Berg D, Weiss NS, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Chanock S, Kraft P. Genome-wide association study of endometrial cancer in E2C2. *Hum Genet* 2014; 133:211-24.
787. Cheng I, Kocarnik JM, Dumitrescu L, Lindor NM, Chang-Claude J, Avery CL, Caberto CP, Love SA, Slattery ML, Chan AT, Baron JA, Hindorff LA, Park SL, Schumacher FR, Hoffmeister M, Kraft P, Butler AM, Duggan DJ, Hou L, Carlson CS, Monroe KR, Lin Y, Carty CL, Mann S, Ma J, Giovannucci EL, Fuchs CS,

Newcomb PA, Jenkins MA, Hopper JL, Haile RW, Conti DV, Campbell PT, Potter JD, Caan BJ, Schoen RE, Hayes RB, Chanock SJ, Berndt SI, Kury S, Bezieau S, Ambite JL, Kumaraguruparan G, Richardson DM, Goodloe RJ, Dilks HH, Baker P, Zanke BW, Lemire M, Gallinger S, Hsu L, Jiao S, Harrison TA, Seminara D, Haiman CA, Kooperberg C, Wilkens LR, Hutter CM, White E, Crawford DC, Heiss G, Hudson TJ, Brenner H, Bush WS, Casey G, Le ML, Peters U. Pleiotropic effects of genetic risk variants for other cancers on colorectal cancer risk: PAGE, GECCO and CCFR consortia. *Gut* 2014; 63:800-7.

788. Clairwood M, Ricketts J, Grant-Kels J, Gonsalves L. Melanoma in skin of color in Connecticut: an analysis of melanoma incidence and stage at diagnosis in non-Hispanic blacks, non-Hispanic whites, and Hispanics. *Int J Dermatol* 2014; 53:425-33.
789. Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, Dupre N, Giovannucci E, Mucci LA. Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. *Eur Urol* 2014; 65:683-9.
790. Huang H, Ma X, Waagepetersen R, Holford T, Wang R, Risch H, Mueller L, Guan Y. A new estimation approach for combining epidemiological data from multiple sources. *Journal of the American Statistical Association* 2014; 109:11-23.
791. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. *AIDS* 2014; 28:881-90.
792. Schildkraut JM, Calvocoressi L, Wang F, Wrensch M, Bondy ML, Wiemels JL, Claus EB. Endogenous and exogenous hormone exposure and the risk of meningioma in men. *J Neurosurg* 2014; 120:820-6.
793. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenwerth AM, Macomber KE, Melville SK, Engels EA. Cancer Treatment Disparities in HIV-Infected Individuals in the United States. *J Clin Oncol*. Epub 30 June 2014.